EP0471493A1 - N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA:cholesterol-acyl transferase - Google Patents
N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA:cholesterol-acyl transferase Download PDFInfo
- Publication number
- EP0471493A1 EP0471493A1 EP19910307196 EP91307196A EP0471493A1 EP 0471493 A1 EP0471493 A1 EP 0471493A1 EP 19910307196 EP19910307196 EP 19910307196 EP 91307196 A EP91307196 A EP 91307196A EP 0471493 A1 EP0471493 A1 EP 0471493A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- amino
- phenyl
- methyl
- dione
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 title 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 123
- 150000001875 compounds Chemical class 0.000 claims abstract description 117
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 89
- -1 cyano, carboxyl Chemical group 0.000 claims abstract description 83
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 18
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 11
- 125000004663 dialkyl amino group Chemical group 0.000 claims abstract description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 10
- 150000002367 halogens Chemical class 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 6
- 125000001424 substituent group Chemical group 0.000 claims abstract description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims abstract description 3
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims abstract description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims abstract description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims abstract description 3
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims abstract description 3
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 215
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 59
- 125000004432 carbon atom Chemical group C* 0.000 claims description 58
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 53
- 150000001412 amines Chemical class 0.000 claims description 11
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- OVMDKFNRWPEAGS-UHFFFAOYSA-N 5-[(2,4-difluoroanilino)-[heptyl-[(4-hexylphenyl)methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(F)C=C(F)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(CCCCCC)C=C1 OVMDKFNRWPEAGS-UHFFFAOYSA-N 0.000 claims description 2
- NHKDVRHYJFEUSR-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[(1-phenylcyclopentyl)methylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC1=CC(OC)=CC=C1NC(NCC1(CCCC1)C=1C=CC=CC=1)=C1C(=O)OC(C)(C)OC1=O NHKDVRHYJFEUSR-UHFFFAOYSA-N 0.000 claims description 2
- QNZZNYFGBZGXBZ-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[2,6-dimethylheptan-4-yl-[[4-(3-methylbutyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC1=CC(OC)=CC=C1NC(N(CC=1C=CC(CCC(C)C)=CC=1)C(CC(C)C)CC(C)C)=C1C(=O)OC(C)(C)OC1=O QNZZNYFGBZGXBZ-UHFFFAOYSA-N 0.000 claims description 2
- MUWKEFLWLRJUBF-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[[4-(2,2-dimethylpropyl)phenyl]methyl-[(1-phenylcyclopentyl)methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC1=CC(OC)=CC=C1NC(N(CC=1C=CC(CC(C)(C)C)=CC=1)CC1(CCCC1)C=1C=CC=CC=1)=C1C(=O)OC(C)(C)OC1=O MUWKEFLWLRJUBF-UHFFFAOYSA-N 0.000 claims description 2
- KVZIOZQQILBENF-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[[4-(2-methylpropyl)phenyl]methyl-(1-morpholin-4-ylpropan-2-yl)amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC1=CC(OC)=CC=C1NC(N(CC=1C=CC(CC(C)C)=CC=1)C(C)CN1CCOCC1)=C1C(=O)OC(C)(C)OC1=O KVZIOZQQILBENF-UHFFFAOYSA-N 0.000 claims description 2
- STZCJGAVLBDIHK-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[heptan-2-yl-[[4-(3-methylbutyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OC)C=C(OC)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(CCC(C)C)C=C1 STZCJGAVLBDIHK-UHFFFAOYSA-N 0.000 claims description 2
- CBANLSBMUOPGCL-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[heptyl-[[4-(3-methylbutoxy)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OC)C=C(OC)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(OCCC(C)C)C=C1 CBANLSBMUOPGCL-UHFFFAOYSA-N 0.000 claims description 2
- YJCSDJWCEZYZLC-UHFFFAOYSA-N 5-[(2,4-dimethylanilino)-[[4-(2,2-dimethylpropyl)phenyl]methyl-heptan-2-ylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(C)C=C(C)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(CC(C)(C)C)C=C1 YJCSDJWCEZYZLC-UHFFFAOYSA-N 0.000 claims description 2
- VBQBBSJHZSRAKU-UHFFFAOYSA-N 5-[(3,5-ditert-butyl-4-hydroxyanilino)-[[4-(2,2-dimethylpropyl)phenyl]methyl-heptylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(CC(C)(C)C)C=C1 VBQBBSJHZSRAKU-UHFFFAOYSA-N 0.000 claims description 2
- JLMJSZDPFXZNPI-UHFFFAOYSA-N 5-[(4-butoxyanilino)-[(4-tert-butylphenyl)methyl-heptan-2-ylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OCCCC)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(C(C)(C)C)C=C1 JLMJSZDPFXZNPI-UHFFFAOYSA-N 0.000 claims description 2
- IBHCBVVUXJFECA-UHFFFAOYSA-N 5-[(4-butoxyanilino)-[(4-tert-butylphenyl)methyl-heptylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OCCCC)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(C(C)(C)C)C=C1 IBHCBVVUXJFECA-UHFFFAOYSA-N 0.000 claims description 2
- HKFTVZYVPRAQIU-UHFFFAOYSA-N 5-[(dihexylamino)-(4-fluoroanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound O=C1OC(C)(C)OC(=O)C1=C(N(CCCCCC)CCCCCC)NC1=CC=C(F)C=C1 HKFTVZYVPRAQIU-UHFFFAOYSA-N 0.000 claims description 2
- DXXACIQPJKXOBY-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-heptylamino]-(2,4,6-trimethoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC=1C=C(OC)C=C(OC)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(C(C)(C)C)C=C1 DXXACIQPJKXOBY-UHFFFAOYSA-N 0.000 claims description 2
- XCMYXPSPXIEWDB-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-heptylamino]-(2,4-difluoroanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(F)C=C(F)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(C(C)(C)C)C=C1 XCMYXPSPXIEWDB-UHFFFAOYSA-N 0.000 claims description 2
- RBQHVSNCUHURLV-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-heptylamino]-(2,4-dimethoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OC)C=C(OC)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(C(C)(C)C)C=C1 RBQHVSNCUHURLV-UHFFFAOYSA-N 0.000 claims description 2
- FHFYZBFWFYVJGF-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-heptylamino]-(4-hexoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OCCCCCC)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(C(C)(C)C)C=C1 FHFYZBFWFYVJGF-UHFFFAOYSA-N 0.000 claims description 2
- ZKZWYJGCOHJEOR-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-heptylamino]-(4-pentoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OCCCCC)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(C(C)(C)C)C=C1 ZKZWYJGCOHJEOR-UHFFFAOYSA-N 0.000 claims description 2
- IPKNTXWSZLZOQL-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-heptylamino]-[4-(dimethylamino)-2,6-dimethylanilino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound CC=1C=C(N(C)C)C=C(C)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(C(C)(C)C)C=C1 IPKNTXWSZLZOQL-UHFFFAOYSA-N 0.000 claims description 2
- YXYQZBUQIOHJNI-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-heptylamino]-[4-(dimethylamino)anilino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(N(C)C)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(C(C)(C)C)C=C1 YXYQZBUQIOHJNI-UHFFFAOYSA-N 0.000 claims description 2
- YJMDWBXZGPMKMT-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-heptylamino]-[4-(trifluoromethyl)anilino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(C(F)(F)F)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(C(C)(C)C)C=C1 YJMDWBXZGPMKMT-UHFFFAOYSA-N 0.000 claims description 2
- STSXULOPCLIVIQ-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-hexylamino]-(4-fluoroanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(F)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCC)CC1=CC=C(C(C)(C)C)C=C1 STSXULOPCLIVIQ-UHFFFAOYSA-N 0.000 claims description 2
- BGCAKGMAXGRXLE-UHFFFAOYSA-N 5-[[4-(dimethylamino)-2,6-dimethylanilino]-[[4-(2,2-dimethylpropyl)phenyl]methyl-heptan-2-ylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound CC=1C=C(N(C)C)C=C(C)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(CC(C)(C)C)C=C1 BGCAKGMAXGRXLE-UHFFFAOYSA-N 0.000 claims description 2
- IVEDLBLTDDBGQI-UHFFFAOYSA-N 5-[[4-(dimethylamino)-2-methylanilino]-[[4-(2,2-dimethylpropyl)phenyl]methyl-heptan-2-ylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(N(C)C)C=C(C)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(CC(C)(C)C)C=C1 IVEDLBLTDDBGQI-UHFFFAOYSA-N 0.000 claims description 2
- QEAYJOGALFYQCR-UHFFFAOYSA-N 5-[[4-(dimethylamino)-2-methylanilino]-[[4-(2,2-dimethylpropyl)phenyl]methyl-heptan-3-ylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(N(C)C)C=C(C)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(CC)CCCC)CC1=CC=C(CC(C)(C)C)C=C1 QEAYJOGALFYQCR-UHFFFAOYSA-N 0.000 claims description 2
- NCMBHBXJRAKPLQ-UHFFFAOYSA-N 5-[[4-(dimethylamino)-2-methylanilino]-[heptan-2-yl-[[4-(3-methylbutyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(N(C)C)C=C(C)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(CCC(C)C)C=C1 NCMBHBXJRAKPLQ-UHFFFAOYSA-N 0.000 claims description 2
- YEXROTKJSIVIGK-UHFFFAOYSA-N 5-[[4-(dimethylamino)anilino]-[6-methylheptan-2-yl-[[4-(2-methylpropyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(N(C)C)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCC(C)C)CC1=CC=C(CC(C)C)C=C1 YEXROTKJSIVIGK-UHFFFAOYSA-N 0.000 claims description 2
- YWEINOSANVASTB-UHFFFAOYSA-N 5-[[4-(dimethylamino)anilino]-[[4-(2,2-dimethylpropyl)phenyl]methyl-heptan-3-ylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(N(C)C)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(CC)CCCC)CC1=CC=C(CC(C)(C)C)C=C1 YWEINOSANVASTB-UHFFFAOYSA-N 0.000 claims description 2
- RVBDDUYJLFUJEU-UHFFFAOYSA-N 5-[[4-(dimethylamino)anilino]-[[4-(2-methylpropyl)phenyl]methyl-tridecan-7-ylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(N(C)C)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(CCCCCC)CCCCCC)CC1=CC=C(CC(C)C)C=C1 RVBDDUYJLFUJEU-UHFFFAOYSA-N 0.000 claims description 2
- INJFMUAVDSEOMZ-UHFFFAOYSA-N 5-[[4-(dimethylamino)anilino]-[heptan-2-yl-[(4-pentylphenyl)methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(N(C)C)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(CCCCC)C=C1 INJFMUAVDSEOMZ-UHFFFAOYSA-N 0.000 claims description 2
- ADFBYICNEHVZQD-UHFFFAOYSA-N 5-[[4-(dimethylamino)anilino]-[heptan-2-yl-[[4-(3-methylbutoxy)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(N(C)C)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(OCCC(C)C)C=C1 ADFBYICNEHVZQD-UHFFFAOYSA-N 0.000 claims description 2
- YJXKLAZIJNVASR-UHFFFAOYSA-N 5-[[heptan-2-yl-[[4-(2-methylpropyl)phenyl]methyl]amino]-(4-hexoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C1=CC(OCCCCCC)=CC=C1NC(N(CC=1C=CC(CC(C)C)=CC=1)C(C)CCCCC)=C1C(=O)OC(C)(C)OC1=O YJXKLAZIJNVASR-UHFFFAOYSA-N 0.000 claims description 2
- ZDMAALWJLSMMQR-UHFFFAOYSA-N 5-[[heptyl-[(4-pentylphenyl)methyl]amino]-[4-(trifluoromethyl)anilino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(C(F)(F)F)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(CCCCC)C=C1 ZDMAALWJLSMMQR-UHFFFAOYSA-N 0.000 claims description 2
- OVJFLKSEDFQCLM-UHFFFAOYSA-N 5-[[heptyl-[[4-(3-methylbutoxy)phenyl]methyl]amino]-(3,4,5-trimethoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C(OC)=C(OC)C(OC)=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(OCCC(C)C)C=C1 OVJFLKSEDFQCLM-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001718 carbodiimides Chemical class 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- WKJZEZTUTXOZGU-UHFFFAOYSA-N 2-methyl-1,3-dioxane-4,6-dione Chemical compound CC1OC(=O)CC(=O)O1 WKJZEZTUTXOZGU-UHFFFAOYSA-N 0.000 claims 1
- PMJQQUGWVIORDG-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[6-methylheptan-2-yl-[[4-(2-methylpropyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC1=CC(OC)=CC=C1NC(N(CC=1C=CC(CC(C)C)=CC=1)C(C)CCCC(C)C)=C1C(=O)OC(C)(C)OC1=O PMJQQUGWVIORDG-UHFFFAOYSA-N 0.000 claims 1
- LGVRWYKMQHXANZ-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[[4-(2,2-dimethylpropyl)phenyl]methyl-heptan-3-ylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OC)C=C(OC)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(CC)CCCC)CC1=CC=C(CC(C)(C)C)C=C1 LGVRWYKMQHXANZ-UHFFFAOYSA-N 0.000 claims 1
- GKJVJFZPNDWUDS-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[heptyl-[(4-pentylphenyl)methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OC)C=C(OC)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(CCCCC)C=C1 GKJVJFZPNDWUDS-UHFFFAOYSA-N 0.000 claims 1
- HOFQIKKOYMWXGG-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[heptyl-[[4-(2-methylpropyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OC)C=C(OC)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(CC(C)C)C=C1 HOFQIKKOYMWXGG-UHFFFAOYSA-N 0.000 claims 1
- VSTNAVBCOYORHZ-UHFFFAOYSA-N 5-[(2,4-dimethoxyphenyl)-[heptan-2-yl-[[4-(3-methylbutoxy)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound O=C1OC(C)(C)OC(=O)C1=C(C=1C(=CC(OC)=CC=1)OC)N(C(C)CCCCC)CC1=CC=C(OCCC(C)C)C=C1 VSTNAVBCOYORHZ-UHFFFAOYSA-N 0.000 claims 1
- HGLFNRGXRCKGSW-UHFFFAOYSA-N 5-[(3,5-ditert-butyl-4-hydroxyanilino)-[[4-(2,2-dimethylpropyl)phenyl]methyl-hexylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCC)CC1=CC=C(CC(C)(C)C)C=C1 HGLFNRGXRCKGSW-UHFFFAOYSA-N 0.000 claims 1
- GWSKIUBKLNKXHT-UHFFFAOYSA-N 5-[(3,5-ditert-butyl-4-hydroxyanilino)-[hexyl-[[4-(2-methylpropyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCC)CC1=CC=C(CC(C)C)C=C1 GWSKIUBKLNKXHT-UHFFFAOYSA-N 0.000 claims 1
- NJBHYAWBCKQODT-UHFFFAOYSA-N 5-[(4-butoxyanilino)-[(4-tert-butylphenyl)methyl-(6-methylheptan-2-yl)amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C1=CC(OCCCC)=CC=C1NC(N(CC=1C=CC(=CC=1)C(C)(C)C)C(C)CCCC(C)C)=C1C(=O)OC(C)(C)OC1=O NJBHYAWBCKQODT-UHFFFAOYSA-N 0.000 claims 1
- TYNAPFZCJFRTFG-UHFFFAOYSA-N 5-[[(1-benzylpiperidin-4-yl)-[[4-(2-methylpropyl)phenyl]methyl]amino]-(2,4-dimethoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC1=CC(OC)=CC=C1NC(N(CC=1C=CC(CC(C)C)=CC=1)C1CCN(CC=2C=CC=CC=2)CC1)=C1C(=O)OC(C)(C)OC1=O TYNAPFZCJFRTFG-UHFFFAOYSA-N 0.000 claims 1
- RILYRGSFPLPBGS-UHFFFAOYSA-N 5-[[(4-butylphenyl)methyl-(6-hydroxy-6-methylheptan-2-yl)amino]-(2,4-dimethoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C1=CC(CCCC)=CC=C1CN(C(C)CCCC(C)(C)O)C(NC=1C(=CC(OC)=CC=1)OC)=C1C(=O)OC(C)(C)OC1=O RILYRGSFPLPBGS-UHFFFAOYSA-N 0.000 claims 1
- SCWOBWDKSKDADT-UHFFFAOYSA-N 5-[[(4-butylphenyl)methyl-(6-hydroxy-6-methylheptan-2-yl)amino]-[4-(dimethylamino)anilino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C1=CC(CCCC)=CC=C1CN(C(C)CCCC(C)(C)O)C(NC=1C=CC(=CC=1)N(C)C)=C1C(=O)OC(C)(C)OC1=O SCWOBWDKSKDADT-UHFFFAOYSA-N 0.000 claims 1
- GXNZMFCHMHMNKL-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-(6-methylheptan-2-yl)amino]-(2,4-dimethoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC1=CC(OC)=CC=C1NC(N(CC=1C=CC(=CC=1)C(C)(C)C)C(C)CCCC(C)C)=C1C(=O)OC(C)(C)OC1=O GXNZMFCHMHMNKL-UHFFFAOYSA-N 0.000 claims 1
- KGHTWMPQGXSNEC-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-decylamino]-(2,4-dimethoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OC)C=C(OC)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCCCCC)CC1=CC=C(C(C)(C)C)C=C1 KGHTWMPQGXSNEC-UHFFFAOYSA-N 0.000 claims 1
- SRECBNFATAVTCU-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-heptan-2-ylamino]-[4-(dimethylamino)anilino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(N(C)C)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(C(C)(C)C)C=C1 SRECBNFATAVTCU-UHFFFAOYSA-N 0.000 claims 1
- XFBSMRFZGPBOFM-UHFFFAOYSA-N 5-[[(4-tert-butylphenyl)methyl-heptylamino]-(4-phenylmethoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OCC=2C=CC=CC=2)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(C(C)(C)C)C=C1 XFBSMRFZGPBOFM-UHFFFAOYSA-N 0.000 claims 1
- LOZFCOFLGALJOJ-UHFFFAOYSA-N 5-[[4-(dimethylamino)anilino]-[(6-hydroxy-6-methylheptan-2-yl)-[[4-(2-methylpropyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C1=CC(CC(C)C)=CC=C1CN(C(C)CCCC(C)(C)O)C(NC=1C=CC(=CC=1)N(C)C)=C1C(=O)OC(C)(C)OC1=O LOZFCOFLGALJOJ-UHFFFAOYSA-N 0.000 claims 1
- JUJZXLRYLSRLDP-UHFFFAOYSA-N 5-[[4-(dimethylamino)anilino]-[[4-(2,2-dimethylpropyl)phenyl]methyl-heptan-2-ylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(N(C)C)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(CC(C)(C)C)C=C1 JUJZXLRYLSRLDP-UHFFFAOYSA-N 0.000 claims 1
- CBOUIJFYMJSVKU-UHFFFAOYSA-N 5-[[cyclohexyl-[[4-(2,2-dimethylpropyl)phenyl]methyl]amino]-(3,5-ditert-butyl-4-hydroxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C1=CC(CC(C)(C)C)=CC=C1CN(C(NC=1C=C(C(O)=C(C=1)C(C)(C)C)C(C)(C)C)=C1C(OC(C)(C)OC1=O)=O)C1CCCCC1 CBOUIJFYMJSVKU-UHFFFAOYSA-N 0.000 claims 1
- NKFLOEVEUAQMBC-UHFFFAOYSA-N 5-[[heptyl-[[4-(3-methylbutoxy)phenyl]methyl]amino]-(3-phenylmethoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=CC(OCC=2C=CC=CC=2)=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(OCCC(C)C)C=C1 NKFLOEVEUAQMBC-UHFFFAOYSA-N 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 abstract description 3
- 239000007787 solid Substances 0.000 description 93
- 238000000921 elemental analysis Methods 0.000 description 80
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 69
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 46
- 239000002904 solvent Substances 0.000 description 45
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 38
- 239000011541 reaction mixture Substances 0.000 description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 25
- 239000000203 mixture Substances 0.000 description 19
- 238000010992 reflux Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000000746 purification Methods 0.000 description 17
- 239000000741 silica gel Substances 0.000 description 17
- 229910002027 silica gel Inorganic materials 0.000 description 17
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- 238000012512 characterization method Methods 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- 229910000372 mercury(II) sulfate Inorganic materials 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- DOBUSJIVSSJEDA-UHFFFAOYSA-L 1,3-dioxa-2$l^{6}-thia-4-mercuracyclobutane 2,2-dioxide Chemical compound [Hg+2].[O-]S([O-])(=O)=O DOBUSJIVSSJEDA-UHFFFAOYSA-L 0.000 description 9
- MANVMTSCCSAYSN-UHFFFAOYSA-N acetonitrile;2-methylpropan-2-ol Chemical compound CC#N.CC(C)(C)O MANVMTSCCSAYSN-UHFFFAOYSA-N 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 229940074994 mercuric sulfate Drugs 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- OCIGQKNRHXFMQJ-UHFFFAOYSA-N 5-[Bis(methylsulfanyl)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound CSC(SC)=C1C(=O)OC(C)(C)OC1=O OCIGQKNRHXFMQJ-UHFFFAOYSA-N 0.000 description 5
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- WJYIASZWHGOTOU-UHFFFAOYSA-N Heptylamine Chemical compound CCCCCCCN WJYIASZWHGOTOU-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VSRBKQFNFZQRBM-UHFFFAOYSA-N tuaminoheptane Chemical compound CCCCCC(C)N VSRBKQFNFZQRBM-UHFFFAOYSA-N 0.000 description 3
- SJWOFBVBNFLWLP-UHFFFAOYSA-N 1-(1-phenylcyclopentyl)methylamine Chemical compound C=1C=CC=CC=1C1(CN)CCCC1 SJWOFBVBNFLWLP-UHFFFAOYSA-N 0.000 description 2
- XEGGPWMGBNKOQH-UHFFFAOYSA-N 4-(2,2-dimethylpropyl)benzoyl chloride Chemical compound CC(C)(C)CC1=CC=C(C(Cl)=O)C=C1 XEGGPWMGBNKOQH-UHFFFAOYSA-N 0.000 description 2
- ZUIMNFHCXYKWGT-UHFFFAOYSA-N 4-amino-2,6-ditert-butylphenol;hydrochloride Chemical compound Cl.CC(C)(C)C1=CC(N)=CC(C(C)(C)C)=C1O ZUIMNFHCXYKWGT-UHFFFAOYSA-N 0.000 description 2
- WNLMYNASWOULQY-UHFFFAOYSA-N 4-tert-butylbenzoyl chloride Chemical compound CC(C)(C)C1=CC=C(C(Cl)=O)C=C1 WNLMYNASWOULQY-UHFFFAOYSA-N 0.000 description 2
- YTWCGZHFHFDEKO-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)methylsulfanylmethylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC1=CC(OC)=CC=C1NCSC=C1C(=O)OC(C)(C)OC1=O YTWCGZHFHFDEKO-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102100030817 Liver carboxylesterase 1 Human genes 0.000 description 2
- 101710181187 Liver carboxylesterase 1 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004903 negative regulation of intestinal cholesterol absorption Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 1
- YXZFFTJAHVMMLF-UHFFFAOYSA-N 1-bromo-3-methylbutane Chemical compound CC(C)CCBr YXZFFTJAHVMMLF-UHFFFAOYSA-N 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- GDXMFFGTPGAGGX-UHFFFAOYSA-N 1-phenylcyclopentane-1-carbonitrile Chemical compound C=1C=CC=CC=1C1(C#N)CCCC1 GDXMFFGTPGAGGX-UHFFFAOYSA-N 0.000 description 1
- CJGXJKVMUHXVHL-UHFFFAOYSA-N 2,2-dimethylpropylbenzene Chemical compound CC(C)(C)CC1=CC=CC=C1 CJGXJKVMUHXVHL-UHFFFAOYSA-N 0.000 description 1
- GEQNZVKIDIPGCO-UHFFFAOYSA-N 2,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C(OC)=C1 GEQNZVKIDIPGCO-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- APGFKFVPGXOPPO-UHFFFAOYSA-N 4-(2-methylpropyl)benzoyl chloride Chemical compound CC(C)CC1=CC=C(C(Cl)=O)C=C1 APGFKFVPGXOPPO-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- PBQHGGFSVWFNIZ-UHFFFAOYSA-N 5-(2,4-dimethoxyanilino)-2-ethenyl-2-methyl-5-methylsulfanyl-1,3-dioxane-4,6-dione Chemical compound COC1=CC(OC)=CC=C1NC1(SC)C(=O)OC(C)(C=C)OC1=O PBQHGGFSVWFNIZ-UHFFFAOYSA-N 0.000 description 1
- VJCFTYFHRVIZNZ-UHFFFAOYSA-N 5-(diaminomethylidene)-1,4-dioxane-2,3-dione Chemical class NC(N)=C1COC(=O)C(=O)O1 VJCFTYFHRVIZNZ-UHFFFAOYSA-N 0.000 description 1
- BDLUSCBUHFMTNU-XMMPIXPASA-N 5-[(2,4-dimethoxyanilino)-[[(2r)-1-hydroxy-4-methylpentan-2-yl]-[[4-(2-methylpropyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound COC1=CC(OC)=CC=C1NC(N(CC=1C=CC(CC(C)C)=CC=1)[C@@H](CO)CC(C)C)=C1C(=O)OC(C)(C)OC1=O BDLUSCBUHFMTNU-XMMPIXPASA-N 0.000 description 1
- FRGOCMFQJDNZAZ-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[[4-(2,2-dimethylpropyl)phenyl]methyl-heptylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OC)C=C(OC)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(CC(C)(C)C)C=C1 FRGOCMFQJDNZAZ-UHFFFAOYSA-N 0.000 description 1
- UMBOTWHGQWPMQM-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[heptan-2-yl-[[4-(2-methylpropoxy)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OC)C=C(OC)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(OCC(C)C)C=C1 UMBOTWHGQWPMQM-UHFFFAOYSA-N 0.000 description 1
- XLWLCDZDWRIGPG-UHFFFAOYSA-N 5-[(2,4-dimethoxyanilino)-[heptyl-[[4-(3-methylbutyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(OC)C=C(OC)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCCC)CC1=CC=C(CCC(C)C)C=C1 XLWLCDZDWRIGPG-UHFFFAOYSA-N 0.000 description 1
- JUFIKHFHECRVQL-UHFFFAOYSA-N 5-[(2,4-dimethylanilino)methylsulfanylmethylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound CC1=CC(C)=CC=C1NCSC=C1C(=O)OC(C)(C)OC1=O JUFIKHFHECRVQL-UHFFFAOYSA-N 0.000 description 1
- FKNHPGYZMFFWBA-UHFFFAOYSA-N 5-[(dihexylamino)-(2,4-dimethoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound O=C1OC(C)(C)OC(=O)C1=C(N(CCCCCC)CCCCCC)NC1=CC=C(OC)C=C1OC FKNHPGYZMFFWBA-UHFFFAOYSA-N 0.000 description 1
- LDCSHUJIFYVXNM-UHFFFAOYSA-N 5-[[3-(dimethylamino)-2-methylanilino]-[heptan-2-yl-[[4-(2-methylpropyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=CC(N(C)C)=C(C)C=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(CC(C)C)C=C1 LDCSHUJIFYVXNM-UHFFFAOYSA-N 0.000 description 1
- XQIOWANYOMVWLQ-UHFFFAOYSA-N 5-[[4-(dimethylamino)anilino]-[2,6-dimethylheptan-4-yl-[[4-(3-methylbutyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C1=CC(CCC(C)C)=CC=C1CN(C(CC(C)C)CC(C)C)C(NC=1C=CC(=CC=1)N(C)C)=C1C(=O)OC(C)(C)OC1=O XQIOWANYOMVWLQ-UHFFFAOYSA-N 0.000 description 1
- DCSBGJQYTZDIOQ-UHFFFAOYSA-N 5-[[4-(dimethylamino)anilino]-[heptan-2-yl-[[4-(3-methylbutyl)phenyl]methyl]amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C=C(N(C)C)C=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(C(C)CCCCC)CC1=CC=C(CCC(C)C)C=C1 DCSBGJQYTZDIOQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BZORFPDSXLZWJF-UHFFFAOYSA-N N,N-dimethyl-1,4-phenylenediamine Chemical compound CN(C)C1=CC=C(N)C=C1 BZORFPDSXLZWJF-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical class CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 1
- MYBBMMORFOKMMQ-UHFFFAOYSA-N acetonitrile;hexane Chemical class CC#N.CCCCCC MYBBMMORFOKMMQ-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000364 effect on atherosclerosis Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- FPFQPLFYTKMCHN-PPHPATTJSA-N ethyl (2s)-2-amino-3-phenylpropanoate;hydron;chloride Chemical compound Cl.CCOC(=O)[C@@H](N)CC1=CC=CC=C1 FPFQPLFYTKMCHN-PPHPATTJSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- KXUHSQYYJYAXGZ-UHFFFAOYSA-N isobutylbenzene Chemical compound CC(C)CC1=CC=CC=C1 KXUHSQYYJYAXGZ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- NPWNVFDQUYBFDS-UHFFFAOYSA-N n-[(4-tert-butylphenyl)methyl]heptan-1-amine Chemical compound CCCCCCCNCC1=CC=C(C(C)(C)C)C=C1 NPWNVFDQUYBFDS-UHFFFAOYSA-N 0.000 description 1
- XCGSKZOHIIYORE-UHFFFAOYSA-N n-[[4-(2,2-dimethylpropyl)phenyl]methyl]cyclohexanamine Chemical compound C1=CC(CC(C)(C)C)=CC=C1CNC1CCCCC1 XCGSKZOHIIYORE-UHFFFAOYSA-N 0.000 description 1
- NOAQIYSFIBXLTR-UHFFFAOYSA-N n-[[4-(2,2-dimethylpropyl)phenyl]methyl]heptan-2-amine Chemical compound CCCCCC(C)NCC1=CC=C(CC(C)(C)C)C=C1 NOAQIYSFIBXLTR-UHFFFAOYSA-N 0.000 description 1
- STFOGBUHCCGQAE-UHFFFAOYSA-N n-[[4-(2-methylpropyl)phenyl]methyl]heptan-2-amine Chemical compound CCCCCC(C)NCC1=CC=C(CC(C)C)C=C1 STFOGBUHCCGQAE-UHFFFAOYSA-N 0.000 description 1
- NMUIIGWVIPTWOL-UHFFFAOYSA-N n-benzyl-n-tert-butylheptan-2-amine Chemical compound CCCCCC(C)N(C(C)(C)C)CC1=CC=CC=C1 NMUIIGWVIPTWOL-UHFFFAOYSA-N 0.000 description 1
- PXSXRABJBXYMFT-UHFFFAOYSA-N n-hexylhexan-1-amine Chemical compound CCCCCCNCCCCCC PXSXRABJBXYMFT-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- This invention relates to N,N′,N′-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-diones, processes for preparing them and pharmaceutical compositions containing them which display inhibition of Acyl-Coenzyme A: Cholesterol Acyltransferase (ACAT).
- ACAT Cholesterol Acyltransferase
- Atherosclerosis is the most common form of arteriosclerosis and is characterized by the buildup of phospholipids and esterified cholesterol in large and medium arteries causing them to be inelastic and thus weakened. These inelastic and occluded arteries are the most common cause of ischemic heart disease.
- ACAT is an important enzyme for the intracellular esterification of cholesterol. Studies of this enzyme in cultured cells (M.S. Brown, J. Biol . Chem . 1980 , 617 , 458) has shown that increases in ACAT activity represent increases in the presence of cholesterol laden lipoproteins. Regulation of ACAT helps prevent the absorption of cholesterol in the intestinal mucosa, and assists in the reversal of already present atherosclerotic lesions.
- X, Y and Z are, independently, hydrogen, halogen, hydroxy, nitro, cyano, carboxyl, trifluoromethyl, phenyl, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group has 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms or aralkoxy of 7 to 10 carbon atoms;
- R1 is alkyl of 1 to 18 carbon atoms, hydroxyalkyl of 1 to 18 carbon atoms, alkenyl of 1 to 18 carbon atoms, cycloalkyl of 5 to 8 carbon atoms, phenylcycloalkyl in which the cycloalkyl moiety has 5 to 8 carbon atoms, 1-hydroxymethylphenethyl, 1-(t-butyl)di
- the halogen substituent referred to above may be chlorine, bromine, fluorine or iodine, fluorine being preferred.
- the pharmaceutically acceptable salts are derived from known inorganic or organic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, toluene sulfonic, naphthalenesulfonic, formic, acetic, propionic, oxalic, succinic, glycollic, lactic, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, pyruvic, phenylacetic, benzoic, para-amino benzoic, para-hydroxybenzoic, salicylic, sulfanilic acids, and the like.
- X, Y and Z are, independently, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, hydroxy, dialkylamino in which each alkyl group has from 1 to 6 carbon atoms or aralkoxy of 7 to 10 carbon atoms;
- R1 is alkyl of 1 to 18 carbon atoms, 1-(t-butyl)dimethylsilyloxymethylphenethyl, 1-(t-butyl)dimethylsilyloxymethylisopentyl, phenylcycloalkyl in which the cycloalkyl group has 5 to 8 carbon atoms or hydroxy alkyl of 1 to 18 carbon atoms; and
- R2 is alkyl- or alkoxy-substituted benzyl, in which the alkyl and alkoxy substituents contain 1 to 6 carbon atoms; or a pharmaceutically acceptable salt thereof.
- This invention also provides processes for preparing the compounds of formula I which comprise
- Examples of leaving groups for L in formula II are -SR and -S(O)R, where R is an organic radical e.g alkyl, aralkyl or aryl such as methyl, phenyl, tolyl or benzyl.
- Both reactions above may be conveniently carried out by mixing the reagents in the presence of an inert solvent with heating if necessary.
- Compounds of formula IV can be prepared by processes known in the art. For example, when L is SR where R is alkyl or aralkyl then compounds of formula can be prepared by reacting Meldrum's acid with CS2 and an organic halide, e.g RI presence of a base such as triethylamine.
- an organic halide e.g RI presence of a base such as triethylamine.
- the compounds of this invention are conveniently prepared by conversion of 2,2-dimethyl-1,3-dioxane-4,6-dione to the corresponding 5-bis (methylthio) methylene derivative with carbon disulfide and methyl iodide in dimethylsulfoxide in the presence of a base such as triethylamine, followed by sequential displacement of the methylthio groups with the desired amines thusly:
- N -t-butylbenzyl-N-(1-methylhexyl)amine was synthesized in the same manner as in Example 2, procedures 1 and 2 using 4- t -butylbenzoyl chloride and 2-aminoheptane as starting materials.
- the ester (Method F, procedure 1) was dissolved in 200 mL of ethanol and 8.8 g (0.22 mol) of NaOH in 70 mL of H2O was added. The reaction mixture srirred at room temperature for 19 h. The ethanol was removed at reduced pressure and the residue added to 300 mL of H2O. The aqueous layer was washed twice with ethyl ether and the aqueous layer acidified with conc. HCl. The aqueous layer was then extracted 3 rimes with ethyl acetate and the ethyl acetate layers were combined, dried (MgSO4) and the solvent removed at reduced pressure. The residue was used as is without further purification or characterization.
- the hydrochloride salt was then basified with aqueous NaOH and extracted 3 times with ethyl ether.
- the ether was dried (Na2SO4) and the solvents were removed at reduced pressure.
- the amine was used without further purification or characterization.
- N -4- [(2,2-dimethylpropyl)phenyl] methyl- N -1 -methylhexyl amine was synthesized as in J . Med . chem . 1986 , 29 , 1131, using 2-aminoheptane and 4-neopentylbenzene as starting materials.
- N -(4-isobutylbenzyl)- N -4-( N′ -benzylpiperidinyl) amine was synthesized as in Method 6, procedure 1 using 4-amino- N -benzylpiperidine and isobutyl benzene as starting materials.
- reaction mixture was allowed to reflux for 18 h, then it was cooled to room temperature, diluted with ethyl acetate and filtered through celite. The solvents were removed at reduced pressure and a column chromatography of the residue on silica gel (10% MeOH-ethyl acetate) yielded 0.73 g of a solid (m.p.
- the oil obtained was dissolved in 150 mL of toluene at 0°C and 294 mL(100 mmol) of 3.4M Red-Al was added dropwise over 15 min. then the reaction mixture was heated to reflux for 3h and cooled to 0°C where the reaction was carefully quenched with sat'd NH4Cl. The toluene was removed at reduced pressure and the residue was acidified to pH2. The aqueous solution was extracted 3 rimes with CHCl3 which was dried (MgSO4) and the solvent was removed at reduced pressure. The salt was added to aqueous base and extracted with CHCl3 which was dried (Na2SO4) and solvent removed at reduced pressure. The oil obtained was used without further purification of characterization.
- IR (KBr) 3240, 2982, 2889, 1700, 1640, 1596, 1567, 1522, 1480 1470, 1456, 1440, 1388, 1367, 1361, 1335, 1318, 1258, 1209, 1158, 1137, 1119, 1088, 1079, 1039, 1012, 937, 837, 789, 704 cm ⁇ 1 ; 1H NMR (400 MHz, CDCl3) ⁇ 7.42-7.26 (m, 9H), 7.01 (d, 2H, J 7.76 Hz), 6.45 (br s, 1H), 3.75 (m, 8H), 2.44 (s, 2H), 2.05-1.4 (m, 16H), 0.88 (s, 9H).
- the amine-hydrochloride salt was triturated with hexane then filtered. The salt was added to 600 mL of H2O and the pH raised to 14 with solid NaOH. This was extracted with diethyl ether (4 x 125 mL). The combined ether layers were dried (Na2SO4) and the solvent removed at reduced pressure. The amine was used without further purification or characterization.
- Representative compounds were further tested in vivo to establish the percent inhibition of cholesterol absorption.
- normal rats were dosed (oral gavage) with 14C-cholesterol plus the test compound. Blood samples taken at six hours and/or intermittently up to twenty-four hours were analyzed and the percent inhibition of cholesterol absorption was calculated.
- representative compounds were studied in vivo in cholesterol-cholic acid fed rats to determine the percent decrease of cholesterol in their plasma.
- This study involves rats which are, prior to testing, trained for one week to eat over a four hour time period each day. Upon initiation of the experiment, the rats diet is supplemented with 1.0 percent cholesterol and 0.25 percent cholic acid. The rats are dosed with the test compound by oral gavage just prior to adjust following the four hour feeding period. This is repeated for four days. On the fifth day, the rats are sacrificed and the total plasma cholesterol content is determined. The percent decrease in elevated plasma cholesterol levels is calculated in comparison with normal-fed controls.
- the compounds of this invention are useful in the treatment of those disease states which are amenable to treatment by reduction of the rate of cholesterol esterification, the rate of accumulation and deposits of cholesteryl esters on arterial walls and the rate of formation of atheromatous lesions.
- the anti-atherosclerotic agents of this invention may be administered to a mammal in need of intracellular cholesteryl ester concentration reduction orally or parenterally in an amount sufficient to inhibit ACAT catalysis of cholesterol esterification.
- antioxidants in the treatment of atherosclerosis is also known to be of therapeutic value.
- the compounds of this invention may be administered by themselves or in combination with pharmaceutically acceptable liquid or solid carriers. Oral administration in conventional formulations as tablets, capsules, powders, or suspensions is preferred.
- a solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilisers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material.
- the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
- the active ingredient is mixed with a carrier having the necessary compression properties in suitable propoitions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient.
- Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
- Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions.
- the active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both of pharmaceutically acceptable oils or fats.
- the liquid carrier can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilisers or osmo-regulators.
- suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g.
- cellulose derivatives preferably sodium carboxymethyl cellulose solution
- alcohols including monohydric alcohols and polyhydric alcohols, e.g., glycols
- oils e.g. fractionated coconut oil and arachis oil
- the carrier can also be an oil ester such as ethyl oleate and isopropyl myristate.
- Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
- the liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellent.
- Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. When the compound is orally active, it can be administered orally either in liquid or solid composition form.
- the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules.
- the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient;
- the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids.
- the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
- the dosage to be used in the treatment of a specific hypercholesterolemic/atherosclerotic condition must be subjectively determined by the attending physician.
- the variables involved include the extent of the disease state, size, age and response pattern of the patient.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
in which X, and Y are, independently, hydrogen, halogen, hydroxy, nitro, cyano, carboxyl, trifluoromethyl, phenyl, amino, alkylamino, dialkylamino, alkyl, alkoxy or phenylalkyloxy; R₁ is hydrogen, alkyl, hydroxyalkyl, alkenyl, cycloalkyl, phenylcycloalkyl, 1-hydroxymethylphenethyl, 1-(t-butyl)dimethylsilyloxymethylphenethyl, 1-(t-butyl)dimenthylsilyloxy methylisopentyl, 1-hydroxymethylisopentyl, phenyl, benzyl or substituted phenyl or benzyl, where the substituents are alkyl, alkoxy, halogen, cyano, trifluoromethyl, amino, alkylamino, dialkylamino, nitro or phenyl, benzyl, phenethyl or R₁ is thienyl, imidazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, benzamidazolyl, phenylalkylpiperidinyl or morpholino; R₂ is alkyl, cycloalkyl, phenyl, benzyl or substituted phenyl or benzyl in which said substituent is alkyl, alkoxy, halogen, cyano, trifluoromethyl amino, nitro, alkylamino or dialkylamino; and a pharmaceutically acceptable salt thereof; are ACAT inhibitors, some of which possess antioxidant properties.
Description
- This invention relates to N,N′,N′-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-diones, processes for preparing them and pharmaceutical compositions containing them which display inhibition of Acyl-Coenzyme A: Cholesterol Acyltransferase (ACAT). Compounds of this type aid in reducing cholesterol absorption and its effect on atherosclerosis.
- Atherosclerosis is the most common form of arteriosclerosis and is characterized by the buildup of phospholipids and esterified cholesterol in large and medium arteries causing them to be inelastic and thus weakened. These inelastic and occluded arteries are the most common cause of ischemic heart disease.
- ACAT is an important enzyme for the intracellular esterification of cholesterol. Studies of this enzyme in cultured cells (M.S. Brown, J. Biol. Chem. 1980, 617, 458) has shown that increases in ACAT activity represent increases in the presence of cholesterol laden lipoproteins. Regulation of ACAT helps prevent the absorption of cholesterol in the intestinal mucosa, and assists in the reversal of already present atherosclerotic lesions.
- In accordance with this invention, there is provided a group of diaminomethylene dioxane dione derivatives of the formula:
in which
X, Y and Z are, independently, hydrogen, halogen, hydroxy, nitro, cyano, carboxyl, trifluoromethyl, phenyl, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group has 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms or aralkoxy of 7 to 10 carbon atoms;
R₁ is alkyl of 1 to 18 carbon atoms, hydroxyalkyl of 1 to 18 carbon atoms, alkenyl of 1 to 18 carbon atoms, cycloalkyl of 5 to 8 carbon atoms, phenylcycloalkyl in which the cycloalkyl moiety has 5 to 8 carbon atoms, 1-hydroxymethylphenethyl, 1-(t-butyl)dimethylsilyloxymethylphenethyl, 1-(t-butyl)dimethylsilyloxymethylisopentyl, 1-hydroxymethylisopentyl, phenyl, benzyl or substituted phenyl or benzyl where the substituents are alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, halogen, cyano, trifluoromethyl, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group has 1 to 6 carbon atoms, nitro or phenyl, benzyl, phenethyl or R₁ is thienyl, imidazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, benzamidazolyl, phenylalkylpiperidinyl in which the alkyl moiety has from 1 to 6 carbon atoms or morpholino, or R¹ is hydrogen;
R₂ is alkyl of 1 to 18 carbon atoms, cycloalkyl of 5 to 8 carbon atoms, phenyl, benzyl or substituted phenyl or benzyl in which said substituent is alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, halogen, cyano, trifluoromethyl amino, nitro, alkymino of 1 to 6 carbon atoms or dialkylamino of 1 to 6 Carbon atoms;
or a pharmaceutically acceptable salt thereof, which compounds are useful as pharmaceuticals. Compounds wherein R¹ is other than hydrogen are included in this invention. - The halogen substituent referred to above may be chlorine, bromine, fluorine or iodine, fluorine being preferred. The pharmaceutically acceptable salts are derived from known inorganic or organic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, toluene sulfonic, naphthalenesulfonic, formic, acetic, propionic, oxalic, succinic, glycollic, lactic, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, pyruvic, phenylacetic, benzoic, para-amino benzoic, para-hydroxybenzoic, salicylic, sulfanilic acids, and the like.
- Of these compounds, those preferred on the basis of their in vitro and in vivo potency are:
in which
X, Y and Z are, independently, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, hydroxy, dialkylamino in which each alkyl group has from 1 to 6 carbon atoms or aralkoxy of 7 to 10 carbon atoms;
R₁ is alkyl of 1 to 18 carbon atoms, 1-(t-butyl)dimethylsilyloxymethylphenethyl, 1-(t-butyl)dimethylsilyloxymethylisopentyl, phenylcycloalkyl in which the cycloalkyl group has 5 to 8 carbon atoms or hydroxy alkyl of 1 to 18 carbon atoms;
and
R₂ is alkyl- or alkoxy-substituted benzyl, in which the alkyl and alkoxy substituents contain 1 to 6 carbon atoms;
or a pharmaceutically acceptable salt thereof. - This invention also provides processes for preparing the compounds of formula I which comprise
- a) reacting a compound of formula
Or - (b) reacting 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's Acid) with a carbodiimide of formula
- Examples of leaving groups for L in formula II are -SR and -S(O)R, where R is an organic radical e.g alkyl, aralkyl or aryl such as methyl, phenyl, tolyl or benzyl.
-
- Both reactions above may be conveniently carried out by mixing the reagents in the presence of an inert solvent with heating if necessary.
- Compounds of formula IV can be prepared by processes known in the art. For example, when L is SR where R is alkyl or aralkyl then compounds of formula can be prepared by reacting Meldrum's acid with CS₂ and an organic halide, e.g RI presence of a base such as triethylamine.
- Oxidation of a compound of formula II wherein L is SR with a peracid e.g m-chloroperbenzoic acid give corresponding compounds where L is S(O)R.
- The compounds of this invention are conveniently prepared by conversion of 2,2-dimethyl-1,3-dioxane-4,6-dione to the corresponding 5-bis (methylthio) methylene derivative with carbon disulfide and methyl iodide in dimethylsulfoxide in the presence of a base such as triethylamine, followed by sequential displacement of the methylthio groups with the desired amines thusly:
- The following examples illustrate without limitation the preparation of representative compounds of this invention.
- To a solution containing 20 g (8.05 mmol) of 5-[bis(methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione 1 in 40 mL of t-butanol, was added 1.23 g (8.05 mmol) of 2,4-dimethoxy aniline. The reaction mixture was allowed to stir at reflux for 24 h. The mixture was cooled to room temperature and diluted with hexanes. The solid was faltered and used without further purification. Isolated: 2.3g, 81% yield.
- To a solution of 0.6 g (1.7 mmol) of 5-[[(2,4-dimethoxyphenyl)amino]methyl-thiomethylene]-2,2-dimethyl-1,3-dioxane-4,6-dione in 22 mL of 50:50 t-butanol-acetonitrile was added 0.395 mL (1.7 mmol) of N-dihexylamine, 0.27 g (0.9 mmol) of mercuric sulfate and 0.23 mL (1.7 mmol) of trimethylamine. The reaction mixture was refluxed for 4 h, then cooled to room temperature. Dilution with 50:50 hexanes-ethyl acetate and filtration through celite followed by removal of solvents under reduced pressure yielded an oil. Column Chromatography on silica gel (1:1 ethyl acetate-hexanes) yielded 0.72 g (87%) of a solid, m.p. 156-157.5°C. TLC (1:1 ethyl acetate-hexane) Rf = 0.09; IR (KBr) 2830, 1696, 1645, 1512, 1208, 940 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 8.33 (s, 1H, exchangeable), 7.06 (d, 1H, J = 8.7 Hz), 6.49 (d, 1H, J = 2.6 Hz), 6.44 (dd, 1H, J = 2.6, 8.7 Hz), 3.82 (s, 3H), 3.80 (s, 3H), 3.21 (m, 4H), 1.64 (s, 6H), 1.59 (s, 4H), 1.27 (m, 12H), 0.87 (t, 6H, J = 6.7 Hz).
- Elemental analysis for:
- C₂₇H₄₂N₂O₆
- Calc'd:
- C, 66.10; H, 8.63; N, 5.71
- Found:
- C, 66.09; H, 8.46; N, 5.70
- To a solution of 37 mL (0.25 mol) 1-heptylamine, 36 mL (0.26 mol) of triethylamine in 300 mL of CHCl₃ was added 49.6 mL (0.25 mol) of 4-t-butyl benzoyl chloride dropwise. The reaction mixture was stirred at room temperature for 20 h then poured into H₂O. The layers were separated and the organic layer washed twice with H₂O. The CHCl₃ layer was dried (MgSO₄) and the solvent removed at reduced pressure. The impure compound was used without further purification.
- To a solution of 68.8 g (0.25 mol) of the amide from procedure 1 in 400 mL of dry toluene was added 105 mL of 70% Red-A1 in toluene, dropwise. The reaction mixture stirred at room temperature for.5 h then at reflux for 15 h. The solution was cooled, quenched with saturated NH₄Cl and the solvent removed under reduced pressure. The residue was taken up in aqueous HCl and the ammonium salt extracted with CHCl₃ three times. The combined organic layers were dried (MgSO₄) and the solvent removed at reduced pressure. The salt was then crystallized from ether, filtered and washed with ether. The ammonium salt was than basified with aqueous NaOH and extracted three times with Et₂O which was dried (Na₂SO₄) and the solvent removed at reduced pressure. This amine was used as is without further purification.
- To a solution of 0.6 g (1.7 mmol) 3-[[(2,4-dimethoxyphenyl)amino]methylthiomethylene]-2,2-dimethyl-1,3-dioxane-4,6-dione (Method A, procedure 1) in 20 mL of 50:50 acetonitrile/t-butanol was added.44 g (1.7 mmol) of N-4-t-butylbenzyl-N-heptylamine (Procedure 2), 0.27 g (0.8 mmol) of mercuric sulfate and 0.23 mL (1.7 mmol) of triethylamine. The solution was refluxed for 4 h and cooled to room temperature. The solution was diluted with ethyl acetate and filtered through celite. The solvents were removed under reduced pressure and chromatography on silica gel (1:1 hexanes-ethyl acetate) yielded 0.81 g (85%) of a white solid (m.p. 100-103°C) homogeneous by TLC and spectroscopic considerations. TLC (1:1 hexanes-ethyl acetate) Rf 0.23; IR (KBr) 2950, 1700, 1630, 1512, 1208, 1035, 931 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.36 (d, 2H, J = 8.3 Hz), 7.23 (d, 2H, J = 8.3 Hz), 7.02 (d, 1H, J = 8.7 Hz), 6.46 (d, 1H, J = 2.6 Hz), 6.37 (dd, 1H, J = 2.6, 8.7 Hz), 4.40 (br s, 2H), 3.78 (s, 3H), 3.77 (s, 3H), 3.13 (m, 2H), 1.63 (s, 6H), 1.31 (s, 9H), 1.17 (br s, 10 H), 0.84 (t, 3H, J = 6.8 Hz).
- Elemental analysis for:
- C₃₃H₄₆N₂O₆
- Calc'd:
- C, 69.94; H, 8.18; N, 4.94
- Found:
- C, 69.81; H, 8.20; N, 4.95
- To a solution of 2.0 g (8.05 mmol) of 5-[bis(methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione 1 in 30 mL of t-butanol was added 0.76 mL (8.05 mmol) of 4-fluoroaniline. The reaction mixture was allowed to stir at reflux for 48 h. The mixture was cooled to room temperature and filtered. 1.97 g (79%) of a yellow solid was isolated and used without further purification or characterization.
- To a solution containing 0.6 g (1.9 mmol) of 3-[[(4-fluorophenyl)amino]methylthio-methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione in 16 mL of 50:50 acetonitrile-t-butanol was added 0.44 mL (1.9 mmol) of dihexylamine, .31 g (1 mmol) of mercuric sulfate and 0.27 mL (1.9 mmol) of triethylamine.The solution was stirred at reflux for 4 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate and filtered through celite. The solvents were removed at reduced pressure and column chromatography of the residue on silica gel (1:1 ethyl acetate-hexanes) yielded 0.60 g (70%) of a white solid (m.p. 145-147°C) homogeneous by spectroscopic criteria. TLC (1:1 ethyl acetate-hexanes) Rf 0.17; IR (KBr) 2968, 2940, 2870, 1699, 1645, 1513, 1345, 1220, 1082, 839 cm⁻¹. ¹H NMR (400 MHz , CDCl₃) δ 9.08 (br s, 1H, exchangeable), 7.08 (m, 4H), 3.16 (t, 4H, J = 7.2 Hz), 1.64 (s, 6H), 1.57 (m, 4H), 1.24 (br s, 12 H), 0.85 (t, 6H, J = 6.8 Hz).
- Elemental analysis for:
- C₂₅H₃₇FN₂O₄
- Calc'd:
- C, 66.96; H, 8.26; N, 6.25
- Found:
- C, 66.80; H, 8.15; N, 6.15
- The N-t-butylbenzyl-N-(1-methylhexyl)amine was synthesized in the same manner as in Example 2, procedures 1 and 2 using 4-t-butylbenzoyl chloride and 2-aminoheptane as starting materials.
- To a solution of 0.62 g (1.75 mmol) of [[(2,4-dimethoxyphenyl)amino]methylthiomethylene]-2,2-dimethyl-1,3-dioxane-4,6-dione (Method A, Procedure 1) in 6 mL of 50:50 acetonitrile-t-butanol was added 0.46 g (1.75 mmol) of N-4-(2,2-dimethylethyl)benzyl-N-heptylamine[synthesized as in Example 2, Procedure 2 from 2-aminoheptane and 4-(2,2-dimethylethyl)benzoyl chloride], 0.31 g (1.05 mmol) mercuric sulfate and 0.25 mL (1.75 mmol) of triethylamine. The reaction mixture stirred at reflux for 18 h. The solution was cooled to room temperature, diluted with ethyl acetate, filtered through celite and the solvents were removed at reduced pressure. Column chromatography of the residue on silica gel (2:1 hexane-ethyl acetate) yielded 0.87 g (75%) of a light yellow solid (m.p. 86-89°C) homogeneous by spectroscopic criteria. Rf (1:1 hexanes-ethyl acetate) 021; IR (KBr) 2960, 1635, 1565, 1515, 1465, 1210, 1160, 935 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, 2H, J = 7.89 Hz), 7.32 (br m, 2H), 7.12 (d, 2H, J = 9.28), 6.36 (m, 3H), 4.64 (br s, 2H), 4.30 (br m, 1H), 3.75 (s, 3H), 3.67 (s, 3H), 1.78 (br m, 2H), 1.58-1.25 (m, 18 H), 0.86 (t, 3H, J = 6.8 Hz).
- Elemental analysis for:
- C₃₃H₄₆N₂O₆
- Calc'd:
- C, 69.94; H, 8.18; N, 4.94
- Found:
- C, 69.01; H, 8.03; N, 4.77
- To a solution of 0.74 g (3.0 mmol) of 5-[bis(methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione 1 in 10 mL of acetonitrile was added 0.41 g (3.0 mmol) of N, N-dimethyl- 1,4-phenylenediamine. The reaction mixture was allowed to reflux for 18 h. After cooling to room temperature, the solvents were removed at reduced pressure and the residue was recrystallized from ethyl acetate - hexanes to yield 0.773 g (77%) of a dark green powder which was used without further characterization.
- To a solution of 0.59 g (1.75 mmol) of [[(2,4-dimethylphenyl)amino]methylthio-methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione (Method E, Procedure 1) in 6 mL of 50:50 acetonitrile-hexanes was added 0.46 g (1.75 mmol) of N-4-(dimethylethyl)-benzyl-N-heptylamine, 0.31 g (1.75 mmol) of mercuric sulfate and 0.25 mL of triethylamine. The reaction mixture was allowed to stir at reflux for 18 h then was cooled to room temperature. The mixture was diluted with ethyl acetate and filtered through celite. The solvent was removed at reduced pressure and the residue chromatographed on silica gel (1:2 hexanes-ethyl acetate to 1:9 hexanes-ethyl acetate) to yield 0.84 g (88%) of a yellow solid (m.p. 103-106°C) homogeneous by spectral considerations. Rf 0.12 (1:1 ethylacetate-hexanes); IR (KBr): 2950, 1622, 1515, 1348, 1196 1078, 920 cm⁻¹ ; ¹H NMR (400 MHz, CDCl₃) δ 7.37 (d, 2H, J = 8.3 H), 7.24 (d, 2H, J = 8.3 Hz), 6.96 (d, 2H, J = 8.8 Hz), 6.60 (d, 2H, J = 8.8 Hz), 4.39 (br s, 2H), 3.09 (br m, 2H), 2.93 (s, 6H), 1.63 (s, 6H), 1.31 (s, 9H), 1.25-1.15 (m, 10H), 0.85 (t, 3H, J = 6.8 Hz).
- Elemental analysis for:
- C₃₃H₄₇N₃O₄
- Calc'd:
- C, 72.10; H, 8.62; N, 7.64
- Found:
- C, 72.21; H, 8.63; N, 7.77
- To a solution of 30 g (0.18 mol) of ethyl-4-hydroxybenzoate in 200 mL of DMSO was added 24.9 g of anhydrous K₂CO₃ and 21.6 mL (0.18 mol) of 1-bromo-3-methyl butane. The reaction mixture was allowed to stir at room temperature for 1 h then at 70°C for 14 h. The mixture was poured into ethyl acetate and washed 4 rimes with H₂O, then the organic layer was dried (MgSO₄) and the solvents removed at reduced pressure. The residue was used without further purification or characterization.
- The ester (Method F, procedure 1) was dissolved in 200 mL of ethanol and 8.8 g (0.22 mol) of NaOH in 70 mL of H₂O was added. The reaction mixture srirred at room temperature for 19 h. The ethanol was removed at reduced pressure and the residue added to 300 mL of H₂O. The aqueous layer was washed twice with ethyl ether and the aqueous layer acidified with conc. HCl. The aqueous layer was then extracted 3 rimes with ethyl acetate and the ethyl acetate layers were combined, dried (MgSO₄) and the solvent removed at reduced pressure. The residue was used as is without further purification or characterization.
- The acid prepared in Method F, procedure 2, was dissolved in 200 mL of CHCl₃ and 23.3. mL (0.26 mol) oxalyl chloride was added at 0°C over 0.5 h period. After 0.5h at 0°C the reaction mixture was warmed to room temperature for 24 h. The solvents were then removed at reduced pressure and vacuum distillation (0.2 mm Hg) yielded 33 g of an oil (b.p. 120-122°C) which was used as is without further characterization of purification.
- To a solution of 10.6 mL (72 mmol) of 1-aminoheptane in 300 mL of CH₂Cl₂ and 10.0 mL (72 mmol) of Et₃N at 0°C, was added 15 g (66 mmol) of 4-[4-methylpentyl]oxy]-benzoyl chloride. The reaction mixture stirred at 0°C for 0.25 h then to room temperature for 16 h. The reaction mixture was poured into CH₂Cl₂ and washed 3 times with H₂O. The organic layer was dried (MgSO₄) and the solvents were removed at reduced pressure. This was used without further characterization or purification.
- To a solution of 19.8 g (65 mmol) of the amide from Method F, procedure 4 in 400 mL of toluene was added at 0°C, 47.7 mL (.162 mol) of Red-Al over a 10 minute period. The solution was then refluxed for 6 h and upon cooling, quenched with sat'd NH₄Cl and the toluene was removed at reduced pressure. To this residue was added 3N HCl to pH 2. The residue was extracted 3 times with CHCl₃ and the combined CHCl₃ layers were dried (MgSO₄) and the solvent removed at reduced pressure. The hydrochloride salt was washed with ethyl ether and filtered. The hydrochloride salt was then basified with aqueous NaOH and extracted 3 times with ethyl ether. The ether was dried (Na₂SO₄) and the solvents were removed at reduced pressure. The amine was used without further purification or characterization.
- To a solution of 0.78 g (2.2 mmol) of 5-[(2,4-dimethoxyphenyl)amino]-5-methylthio- methylene-2,2-dimethyl-1,3 dioxane-4,6-dione in 8 mL of 50:50 acetonitrile-t-butanol was added 0.67 g (2.3 mmol) of N-[(4-methylpentyl)oxy]phenyl]methyl-N-heptylamine, 0.38 g (1.32 mmol) of mercuric sulfate and 0.31 mL (2.2 mmol) of Et₃N. The reaction mixture was allowed to stir at reflux for 18 h. The mixture was cooled to room temperature, diluted with ethyl acetate and filtered through celite. The solvents were removed at reduced pressure and column chromatography of the residue on silica gel (1:1 ethyl acetate-hexanes then 4:1ethyl acetate-hexanes) yielded 1.25 g (95%) of a pale yellow solid (m.p. 67-70°C). Rf 0.12 (1:1 ethyl acetate-hexanes); IR (KBr) 2940, 2888, 1710, 1640, 1522, 1215, 1042, 938 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.22 (d, 2H, J = 8.6 Hz), 7.03 (d, 1H, J = 8.7 Hz), 6.86 (d, 2H, J = 8.6 Hz), 6.46 (d, 1H, J = 2.6 Hz), 6.38 (m, 1H), 4.34 (br s, 2H), 3.98 (t, 2H, J = 6.7 Hz), 3.79 (s, 3H), 3.78 (s, 3H), 3.08 (m, 2H), 1.83 (m, 1H), 1.70-1.65 (m, 8H), 1.30-1.16 (m, 10H), 0.96 (d, 6H, J = 6.6 Hz), 0.85 (t, 3H, J = 7.1 Hz).
- Elemental analysis for:
- C₃₄H₄₈N₂O₇
- Calc'd:
- C, 68.43; H, 8.11; N, 4.69
- Found:
- C, 68.42; H, 8.36; N, 4.67
- The N-4- [(2,2-dimethylpropyl)phenyl] methyl-N-1 -methylhexyl amine was synthesized as in J. Med. chem. 1986, 29, 1131, using 2-aminoheptane and 4-neopentylbenzene as starting materials.
- To a solution of 0.71 g (2.0 mmol) of 5-[(2,4-dimethoxyphenyl)amino]-5-methylthiomethylene-2,2-dimethyl-1,3 dioxane-4,6-dione in 6 mL of 50:50 acetonitrile-t-butanol was added 0.55 g (2.0 mmol) of the N-4-neopentylbenzyl-N-2-heptylamine (Method 6, procedure 1), 0.35 g (1.2 mmol) mercuric sulfate and 0.28 mL (2.0 mmol) of Et₃N. The reaction mixture was allowed to reflux for 18 h then cooled to room temperature. The solution was diluted with ethyl acetate, filtered through celite and the solvents removed under reduced pressure. Column chromatography of the residue on silica gel (1:1 ethyl acetate-hexanes to 4:1 ethyl acetate-hexanes) yielded after recrystallization (ethyl acetate-hexanes) 102 g (88%) of a white solid (m.p 157-158°C) homogeneous by spectral considerations TLC (1:1 ethyl acetate-hexanes) Rf 0.07; IR (KBr) 2960, 1703, 1640, 1569, 1516, 1211, 938 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.30 (m, 2H), 7.21 (m, 3H), 6.34 (m, 2H), 4.64 (br s, 2H), 4.25 (br m, 1H), 3.66 (s, 3H), 3.64 (s, 3H), 2.45 (s, 2H), 1.76-1.19 (br m, 17H), 0.86 (br s, 12H).
- Elemental analysis for:
- C₃₄H₄₈N₂O₆
- Calc'd:
- C, 70.32; H, 8.33; N, 4.82
- Found:
- C, 70.34; H, 8.37; N, 4.79
- The N-(4-isobutylbenzyl)-N-4-(N′-benzylpiperidinyl) amine was synthesized as in Method 6, procedure 1 using 4-amino-N-benzylpiperidine and isobutyl benzene as starting materials.
- To a solution of 0.71 g (2.0 mmol) of 5-[(2,4-dimethoxyphenyl)amino]-5-methylthiomethylene-2,2-dimethyl-1,3-dioxane-4,6-dione in 20 mL of acetonitrile was added 0.67 g (2.0 mmol) N-(4-isobutylbenzyl)-N-4-(N′-benzylpiperidinyl) amine, 0.35 g (1.2 mmol) HgSO₄ and 0.28 mL (21.0 mmol) of Et₃N. The reaction mixture was allowed to reflux for 18 h, then it was cooled to room temperature, diluted with ethyl acetate and filtered through celite. The solvents were removed at reduced pressure and a column chromatography of the residue on silica gel (10% MeOH-ethyl acetate) yielded 0.73 g of a solid (m.p. 115-118°C); IR (KBr) 3410, 3212, 2935, 1692, 1622, 1558, 1504, 1455, 1372, 1328, 1300, 1245, 1198, 1148, 1071, 1018, 990, 915, 819, 773, 718 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.31-7.21 (m, 7H), 7.14 (d, 2H, J = 7.64 Hz), 7.07 (d, 1H, J = 8.4 Hz), 6.34 (d, 2H, J = 8.64 Hz), 4.72 (br m, 2H), 4.18 (br m, 1H), 3.73 (s, 3H), 3.65 (s, 3H), 3.43 (s, 2H), 2.87 (br d, 2H, J = 10.28 Hz), 2.45 (d, 2H, J = 7.2 Hz), 1.98-1.30 (br m, 14H), 0.87 (d, 6H, J = 6.56 Hz).
- Elemental analysis for:
- C₃₈H₄₇N₃O₆
- Calc'd:
- C, 71.11; H, 7.38; N, 6.55
- Found:
- C, 70.80; H, 7.67; N, 6.54
- To a solution of 25 g (0.14 mol) of 1-cyano-1-phenylcyclopentane in 400 mL of toluene at 0°C was added 107 mL (0.36 mol) of 3.4M Red-Al over a 20 minute period. The reaction mixture was allowed to stir for an additional 23 h at room temperature when it was quenched with sat'd NH₄Cl and the solvent removed at reduced pressure. The residue was added to aqueous acid and extracted four rimes with CHCl₃, which were combined, dried (MgSO₄) and the solvent removed at reduced pressure. The hydrochloride salt was triturated with ethyl ether and then added to aqueous NaOH and extracted 3 rimes with ether. The combined ether layers were dried (Na₂SO₄) and the solvent removed at reduced pressure. The oil was used as is without further purification or characterization.
- To a solution of 0.44 g (2.5 mmol) of 1-aminomethyl-1 -phenylcyclopentane in 20 mL of 1:1 t-butanol-acetonitrile was added 0.88 g (2.5 mmol) of 5-[(2,4-dimethoxyphenyl)amino]-5-methylthiomethylene-2,2-dimethyl-1,3-dioxane-4,6-dione and 0.35 mL (2.5 mmol) of Et₃N. The mixture was allowed to reflux for 4 days then stir at room temperature for 3 days. The solvents were removed at reduced pressure and chromatography on silica gel (2:1 hexanes-ethyl acetate) yielded a solid (m.p. 49-52°C); IR (KBr) 3440, 2962, 2880, 16601413, 1465, 1395, 1348, 1312, 1265, 1210, 1172, 1111, 1029, 923, 798, 765, 701 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 10.90 (br s, 1H), 9.82 (br s, 1H), 7.33-7.18 (m, 5H), 6.93 (d, 1H, J = 8.44 Hz), 6.48 (d, 1H, J = 2.56 Hz), 6.45 (dd, 1H, J = 8.52, 2.64 Hz), 3.85 (s, 3H), 3.78 (s, 3H), 2.88 (d, 2H, J = 4.88 Hz), 1.90-1.51 (m, 14H).
- Elemental analysis for:
- C₂₇H₃₂N₂O₆
- Calc'd:
- C, 67.48; H, 6.71; N, 5.83
- Found:
- C, 67.19; H; 6.64; N, 5.62
- To a solution of 7.0 g (40.0 mmol) of 1-aminomethyl-1-phenyl cyclopentane (Method I, procedure 1) 11.2 mL (80.0 mmol) of Et₃N and 125 mL of CHCl₃ at 0°C was added 8.4 g (400 mmol) of 4-neopentylbenzoyl chloride. After addition the flask was warmed to room temperature and the mixture was stirred for 2h. The mixture was poured into CHCl₃ and washed 3 times with H₂O then dried (MgSO₄)) and the solvents removed at reduced pressure. The oil obtained was dissolved in 150 mL of toluene at 0°C and 294 mL(100 mmol) of 3.4M Red-Al was added dropwise over 15 min. then the reaction mixture was heated to reflux for 3h and cooled to 0°C where the reaction was carefully quenched with sat'd NH₄Cl. The toluene was removed at reduced pressure and the residue was acidified to pH2. The aqueous solution was extracted 3 rimes with CHCl₃ which was dried (MgSO₄) and the solvent was removed at reduced pressure. The salt was added to aqueous base and extracted with CHCl₃ which was dried (Na₂SO₄) and solvent removed at reduced pressure. The oil obtained was used without further purification of characterization.
- To a solution of 1.24 g (3.5 mmol) of 5-[(2,4-dimethoxyphenyl)amino]-5-methylthiomethylene-2,2-dimethyl-1,3-dioxane-4,6-dione, 0.61 g (2.1 mmol) HgSO₄ and 0.49 mL (3.5 mmol) of Et₃N in 40 mL of 1:2 t-butanol-acetonitrile was added 1.17 g (3.5 mmol) of the amine from Method J, procedure 1. The reaction mixture was allowed to stir at reflux for 18h when it was then cooled and the solvents removed at reduced pressure. The residue was then dissolved in CHCl₃ and filtered through celite. Removal of the solvents under reduced pressure and column chromatography of the residue on silica gel (1:2 to 1:4 hexanes-ethyl acetate) yielded 1.84 g (82%) of a solid (m.p. 218-219°C) homogeneous by TLC and spectroscopic considerations. IR (KBr) 3240, 2982, 2889, 1700, 1640, 1596, 1567, 1522, 1480 1470, 1456, 1440, 1388, 1367, 1361, 1335, 1318, 1258, 1209, 1158, 1137, 1119, 1088, 1079, 1039, 1012, 937, 837, 789, 704 cm⁻¹ ; ¹H NMR (400 MHz, CDCl₃) δ 7.42-7.26 (m, 9H), 7.01 (d, 2H, J = 7.76 Hz), 6.45 (br s, 1H), 3.75 (m, 8H), 2.44 (s, 2H), 2.05-1.4 (m, 16H), 0.88 (s, 9H).
- Elemental analysis for:
- C₃₉H₄₈N₂O₆·0.5 H₂O
- Calc'd:
- C, 72.08; H, 7.60; N, 4.30
- Found:
- C, 72.10; H, 7.56; N, 4.56
- To a solution of 12.0 g (52.2 mmol) of L-phenylalanine ethyl ester hydrochloride in 350 mL of CH₂Cl₂ and 16.0 mL (0.115 mol) Et₃N at 0°C was added 10.3 mL (52.2 mmol) of 4-isobutylbenzoyl chloride in 70 mL of CHCl₃. The reaction mixture stirred at 0°C for 0.5h then to room temperature for 20h. The reaction mixture was then washed 3 rimes with H₂O, dried (MgSO₄) and the solvent removed at room temperature to yield 17.9 g (97%) of a solid which was used without further purification or characterization.
- To a solution of 9.9 g (28.0 mmol) of the amide produced in Method K, procedure 1 in 400 mL of toluene was added 20.6 mL (70.0 mmol) of a 3.4M solution of Red-Al, dropwise. After complete addition, the reaction mixture was refluxed for 19h. The reaction mixture was cooled to room temperature and quenched with sat'd NH₄Cl. The toluene was removed at reduced pressure and the residue was poured into aqueous acid. The aqueous layer was then extracted 3 times with CHCl₃. The CHCl₃ layers were combined, dried (MgSO₄) and the solvent removed at reduced pressure. The salt obtained was washed with ether and added to aqueous NaOH. The aqueous layer was extracted 3 times with CH₂Cl₂ which were combined, dried (Na₂SO₄) and the solvent removed at reduced pressure. 5.4 g (65%) of a white solid was isolated and used accordingly.
- To a solution of 1.04 g (3.5 mmol) of the amine from Method K, procedure 2 in 20 mL of CH₂Cl₂ at 0°C was added 2.1 g (7.35 mmol) of tert-butyldimethylsilyl chloride and 1.2 mL (8.4 mmol) of Et₃N. The reaction mixture was stirred at 0°C for 5 min. then it was raised to room temperature and stirred for 18h. The mixture was washed with H₂O, sat'd NaHCO₃ and sat'd NaCl, then dried (Na₂SO₄) and the solvent was removed at reduced pressure. The oily solid (1.3 g) was used without further purification or characterization.
- To a solution of 1.3 g (3.16 mmol) of the amine synthesized in Method K, procedure 3, in 50 mL of 1:1 acetonitrile-t-butanol was added 1.12 g (3. 16 mmol) of 4-[(2,4-dimethoxyphenyl)amino]-5-methylthiomethylene-2,2-dimethyl-1,3-dioxane-4,6-dione, 0.55 g (1.89 mmol) HgSO₄ and 0.44 mL (3.16 mmol) of Et₃N. The reaction mixture stirred at reflux for 18h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and filtered through celite. The solvents were removed at reduced pressure and column chromatography of the residue on silica gel (1:2 to 2:1 ethyl acetate-hexane) yielded 1.0 g (44%) of a white solid (m.p. 123-124°C) homogeneous by spectroscopic considerations. IR (KBr) 3480, 2935, 2904, 2838, 1690, 1628, 1556, 1503, 1456, 1377, 1333, 1300, 1245, 1198, 1148, 1088, 1068, 1027, 920, 825, 773 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.33-7.23 (m, 8H), 7.11 (d, 2H, J = 7.88 Hz), 6.44 (m, 2H), 4.84 (m, 1H), 4.64 (m, 1H), 4.18 (m, 1H), 3.77 (br s, 6H), 3.43 (m, 1H), 3.20 (m, 3H), 2.44 (d, 2H, J = 7.28 Hz), 1.83 (m, 1H), 1.55 (br s, 6H), 0.88 (d, 6H, J = 6.64 Hz), 0.75 (s, 9H), -0.12 (s, 3H), -0.15 (s, 3H).
- Elemental analysis for:
- C₄₁H₅₆N₂O₇Si
- Calc'd:
- C, 68.68; H, 7.87; N, 3.91
- Found:
- C, 68.53; H, 7.86; N, 3.72
- To a solution of 0.57 g (0.8 mmol) of compound 11 in 20 mL of tetrahydrofuran at room temperature was added 0.96 mL (0.96 mol) of 1M tetrabutylammonium fluoride. After 66h the reaction was halted and the solvents removed at reduced pressure. Column chromatography of the residue on silica gel (2% methanol-chloroform) yielded 0.43 g (90%) of a solid (m.p. 167-168°C); IR (KBr) 3250, 2941, 1683, 1625, 1565, 1505, 1448, 1429, 1412, 1376, 1351, 1302, 1258, 1201, 1152, 1093, 1029, 1019, 918, 824, 692 cm⁻¹.
- Elemental analysis for:
- C₃₅H₄₂N₂O₇
- Calc'd:
- C, 69.75; H, 7.02; N, 4.65
- Found:
- C, 69.53; H, 7.21; N, 4.37
- To a solution of 1.8 g (7.25 mmol) of 5-[bis(methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione in 15 mL of degassed acetonitrile was added 2.0 g of 3,5-di-t-butyl-4-hydroxyaniline hydrochloride and 1.01 mL of Et₃N. The reaction mixture was allowed to stir at reflux for 48h. The organic layer was then diluted with CHCl₃, washed twice with H₂O, dried (MgSO₄) and the solvents were removed at reduced pressure. Column chromatography (silica gel) was performed on the residue (3:1 to 2:1 hexanes-ethyl acetate) to yield 1.2 g of a yellow solid which by TLC showed two overlapping spots. This impure mixture was used without further purification or characterization.
- To a solution of 0.6 g (1.4 mmol) of the compound from Method M, procedure 1 in 20 mL of acetonitrile was added 0.37 g (1.4 mmol) of N-4-isobutylbenzyl-N--2-heptylamine, 0.22 g (0.77 mmol) HgSO₄ and 0.19mL (1.4 mmol) of Et₃N. The reaction mixture was allowed to reflux for 19h. Upon cooling the reaction mixture was diluted with EtOAc and filtered through celite and the solvents removed at reduced pressure. Column chromatography of the residue on silica gel (3:1 to 1:1 hexanes-ethyl acetate) yielded 0.36 g (46%) of a solid (dec 202°C) homogeneous by spectroscopic considerations. IR (KBr) 3600, 3402, 2944, 2908, 2858, 1693, 1618, 1566, 1459, 1428, 1382, 1361, 1249, 1225, 1196 1148, 1077, 1010, 920, 880 cm⁻¹ ; ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.17 (m, 4H), 6.81 (br s, 2H), 5.20 (s, 2H), 4.56 (br m, 1H), 2.43 (d, 2H, J = 7.04), 1.82-1.02 (m, 33H), 0.86 (m, 12H).
- Elemental analysis for:
- C₃₉H₅₈N₂O₅
- Calc'd:
- C, 73.78; H, 9.21; N, 4.41
- Found:
- C, 73.43; H, 9.00; N, 4.31
- This compound was synthesized according to the procedure outlined in Method D to yield a solid (m.p. 68-71 °C).
- Elemental analysis for:
- C₃₄H₄₈N₂O₆
- Calc'd:
- C, 70.31; H, 8.33; N, 4.82
- Found:
- C, 70.71; H, 8.46; N, 4.78
- This compound was synthesized according to the procedure outlined in Method C to yield a solid (m.p. 180-181°C).
- Elemental analysis for:
- C₃₁H₄₀F₂N₂O₄
- Calc'd:
- C, 68.61; H, 7.43; N, 5.16
- Found:
- C, 68.80; H, 7.50; N, 5.05
- This compound was synthesized according to the procedure outlined in Method E to yield a solid (m.p. 185-187°C).
- Elemental analysis for:
- C₃₅H₅₁N₃O₄
- Calc'd:
- C, 72.75; H, 8.90; N, 7.27
- Found:
- C, 73.00; H, 8.99; N, 7.15
- This compound was synthesized according to the procedure outlined in Method D to yield a solid (m.p. 88-93°C).
- Elemental analysis for:
- C₃₃H₄₃F₃N₂O₄
- Calc'd:
- C, 67.63; H, 7.56; N, 4.73
- Found:
- C, 67.52; H, 7.69; N, 4.76
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 70-72°C).
- Elemental analysis for:
- C₃₃H₄₄F₂N₂O₄
- Calc'd:
- C, 69.45; H, 7.77; N, 4.91
- Found:
- C, 69.37; H, 7.72; N, 4.90
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 75-78°C).
- Elemental analysis for:
- C₃₅H₅₀N₂O₅
- Calc'd:
- C, 72.63; H, 8.71; N, 4.84
- Found:
- C, 72.83; H, 8.88; N, 4.76
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 176-177°C).
- Elemental analysis for:
- C₃₄H₄₈N₂O₇
- Calc'd:
- C, 68.43; H, 8.11; N, 4.69
- Found:
- C, 68.71; H, 8.42; N, 4.86
- This compound was synthesized according to the procedure outlined in Method D to yield a solid (mp. 119-122°C).
- Elemental analysis for:
- C₃₃H₄₇N₃O₄
- Calc'd:
- C, 72.10; H, 8.62; N, 7.64
- Found:
- C, 72.28; H, 8.93; N, 7.64
- This compound was synthesized according to the procedure outlined in Method F to yield a solid (m.p 76-80°C).
- Elemental analysis for:
- C₃₄H₄₉N₃O₅
- Calc'd:
- C, 70.43; H, 8.51; N, 7.25
- Found:
- C, 70.47; H, 8.71; N, 7.23
- This compound was synthesized according to the procedure outlined in Method F to yield a solid (m.p. 71-74°C).
- Elemental analysis for:
- C₃₅H₅₀N₂O₈
- Calc'd:
- C, 67.07; H, 8.04; N, 4.47
- Found:
- C, 67.13; H, 7.97; N, 4.45
- This compound was synthesized according to the procedure outlined in Method E to yield a solid (m.p 78-80°C).
- Elemental analysis for:
- C₃₆H₅₂N₂O₅
- Calc'd:
- C, 72.94; H, 8.84; N, 4.72
- Found:
- C, 72.86; H, 8.83; N, 4.68
- This compound was synthesized according to the procedure outlined in Method E to yield a solid (m.p. 62-65°C).
- Elemental analysis for:
- C₃₇H₅₄N₂O₅
- Calc'd:
- C, 73.23; H, 8.97; N, 4.62
- Found:
- C, 73.06; H, 8.84; N, 4.56
- This compound was synthesized according to the procedure outlined in Method B to yield a solid (m.p. 81-84°C).
- Elemental analysis for:
- C₃₈H₄₈N₂O₅
- Calc'd:
- C, 74.48; H, 7.90; N, 4.57
- Found:
- C, 74.49; H, 7.93; N, 4.51
- This compound was synthesized according to the procedure outlined in Method D to yield a solid (m.p. 147-151°C).
- Elemental analysis for:
- C₃₅H₅₀N₂O₅
- Calc'd:
- C, 72.63; H, 8.71; N, 4.84
- Found:
- C, 72.91; H, 8.76; N, 4.82
- This compound was synthesized according to the procedure outlined in Method D to yield a solid (m.p. 155-156°C).
- Elemental analysis for:
- C₃₆H₅₂N₂O₅
- Calc'd:
- C, 72.94; H, 8.84; N, 4.72
- Found:
- C, 72.54; H, 8.83; N, 4.90
- This compound was synthesized according to the procedure outlined in Method D to yield a solid (m.p. 92-95°C).
- Elemental analysis for:
- C₃₄H₄₈N₂O₆
- Calc'd:
- C, 70.32; H, 8.33; N, 4.82
- Found:
- C, 70.02; H, 8.28; N, 4.77
- This compound was synthesized according to the procedure outlined in Method B to yield a solid (m.p. 110-112°C).
- Elemental analysis for:
- C₃₂H₄₁F₃N₂O₄
- Calc'd:
- C, 66.88; H, 7.19; N, 4.87
- Found:
- C, 66.59; H, 6.94; N, 4.72
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 81-84°C).
- Elemental analysis for:
- C₃₃H₄₆N₂O₆
- Calc'd:
- C, 69.94; H, 8.18; N, 4.94
- Found:
- C, 69.60; H, 8.25; N, 4.73
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 152-155°C).
- Elemental analysis for:
- C₃₃H₄₆N₂O₆
- Calc'd:
- C, 69.94; H, 8.18; N, 4.94
- Found:
- C, 69.60; H, 8.30; N, 4.93
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 176-177°C).
- Elemental analysis for:
- C₃₆H₅₃N₃O₄
- Calc'd:
- C, 73.06; H, 9.03; N, 7.10
- Found:
- C, 72.74; H, 9.05; N, 7.43
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 103-105°C).
- Elemental analysis for:
- C₃₈H₄₈N₂O₅
- Calc'd:
- C, 74.48; H, 7.89; N, 4.57
- Found:
- C, 74.46; H, 7.86; N, 4.48
- This compound was synthesized according to the procedure outlined in Method F to yield a solid (m.p. 133-135°C).
- Elemental analysis for:
- C₃₄H44₄₈N₂O₄
- Calc'd:
- C, 68.43; H, 8.11; N, 4.69
- Found:
- C, 68.48; H, 8.35; N, 4.66
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 128-130°C).
- Elemental analysis for:
- C₃₉H₅₉N₃O₄
- Calc'd:
- C, 73.89; H, 9.38; N, 6.63
- Found:
- C, 73.57; H, 9.38; N, 7.00
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 145-149°C).
- Elemental analysis for:
- C₃₄H₄₉N₅O₄
- Calc'd:
- C, 72.43; H, 8.76; N, 7.45
- Found:
- C, 72.12; H, 8.78; N, 7.38
- This compound was synthesized according to the procedure outlined in Method F to yield a solid (m.p. 126-128°C).
- Elemental analysis for:
- C₃₄H₄₉N₃O₅
- Calc'd:
- C, 70.44; H, 8.52; N, 7.25
- Found:
- C, 70.28; H, 8.55; N, 7.24
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 152- 154°C).
- Elemental analysis for:
- C₃₄H₄₈N₂O₆
- Calc'd:
- C, 70.32; H, 8.33; N, 4.82
- Found:
- C, 70.14; H, 8.30; N, 4.81
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 130-132°C).
- Elemental analysis for:
- C₃₄H₄₈N₂O₆
- Calc'd:
- C, 70.32; H, 8.33; N, 4.82
- Found:
- C, 70.10; H, 8.52; N, 4.89
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 163-164°C).
- Elemental analysis for:
- C₃₄H₄₉N₃O₄
- Calc'd:
- C, 72.43; H, 8.76; N, 7.45
- Found:
- C, 72.73; H, 9.11; N, 7.43
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 175-177°C).
- Elemental analysis for:
- C₃₄H₄₉N₃O₄
- Calc'd:
- C, 72.44; H, 8.76; N, 7.45
- Found:
- C, 72.60; H, 9.07; N, 7.56
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 63-66°C).
- Elemental analysis for:
- C₃₇H₅₄N₂O₅
- Calc'd:
- C, 73.23; H, 8.97; N, 4.62
- Found:
- C, 73.39; H, 9.28; N, 4.76
- This compound was synthesized according to the procedure outlined in Method G. to yield a solid, hemihydrate (m.p.85-88°C).
- Elemental analysis for:
- C₃₄H₄₈N₂O₇·0.5 H₂O
- Calc'd:
- C, 67.41; H, 8.15; N, 4.62
- Found:
- C, 67.21; H, 7.79; N, 4.64
- This compound was synthesized according to the procedure outlined in Method G to yield a solid, hydrate (m.p. 92-95°C).
- Elemental analysis for:
- C₃₄H₄₉N₃O5·H₂O
- Calc'd:
- C, 68.31; H, 8.60; N, 7.03
- Found:
- C, 68.26; H, 8.61; N, 7.31
- This compound was synthesized according to the procedure outlined in Method E to yield a solid (m.p. 122-124°C).
- Elemental analysis for:
- C₃₄H₄₉N₃O₄
- Calc'd:
- C, 72.43; H, 8.76; N, 7.45
- Found:
- C, 72.24; H, 8.96; N, 7.54
- This compound was synthesized according to the procedure outlined in Method E to yield a solid (m.p. 125-128°C).
- Elemental analysis for:
- C₃₅H₅₁N₃O₄
- Calc'd:
- C, 72.75; H, 8.89; N, 7.27
- Found
- C, 72.41; H, 9.22; N, 7.32
- This compound was synthesized according to the procedure outlined in Method B to yield a solid (m.p. 86-89°C).
- Elemental analysis for:
- C₃₉H₄₈N₂O₆
- Calc'd:
- C, 70.32; H, 8.33; N, 4.82
- Found:
- C, 70.18; H, 8.50; N, 4.91
- This compound was synthesized according to the procedure outlined in Method H to yield a solid (m.p. 140-142°C).
- Elemental analysis for:
- C₃₈H₄₈N₄O₄
- Calc'd:
- C, 73.05; H, 7.74; N, 8.97
- Found:
- C, 72.87; H, 7.83; N, 8.96
- This compound was synthesized according to the procedure outlined in Method H to yield a solid (m.p. 108-112°C).
- Elemental analysis for:
- C₃₃H₄₅N₃O₇
- Calc'd:
- C, 66.53; H, 7.61; N, 7.05
- Found:
- C, 66.71; H, 7.68; N, 6.95
- This compound was synthesized according to the procedure outlined in Method H to yield a solid (m.p. 144-148°C).
- Elemental analysis for:
- C₃₃H₄₆N₄O₅
- Calc'd:
- C, 68.49; H, 8.01; N, 9.68
- Found:
- C, 68.27; H, 8.02; N, 9.52
- This compound was synthesized according to the procedure outlined in Method G to yield a solid, hydrate (m.p. 80-83°C).
- Elemental analysis for:
- C₃₄H₄₈N₂O₇·H₂O
- Calc'd:
- C, 66.42; H, 8.20; N, 4.56
- Found:
- C, 66.38; H, 7.87; N, 4.44
- This compound was synthesized according to the procedure outlined in Method G to yield a solid, 0.75 hydrate (m.p. 110-111°C).
- Elemental analysis for:
- C₃₄H₄₉N₃O₅·0.75 H₂O
- Calc'd:
- C, 68.83; H, 8.58; N, 7.08
- Found:
- C, 68.84; H, 8.20; N, 7.02
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 115-117°C).
- Elemental analysis for:
- C₃₅H₅₁N₃O₄
- Calc'd:
- C, 72.76; H, 8.90; N, 7.27
- Found:
- C, 72.65; H, 9.02; N, 7.17
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 129-131°C).
- Elemental analysis for:
- C₃₄H₄₈N₂O₆
- Calc'd:
- C, 70.32; H, 8.33; N, 4.82
- Found:
- C, 70.55; H, 8.49; N, 5.00
- This compound was synthesized according to the procedure outlined in Scheme G to yield a solid (m.p. 124-126).
- Elemental analysis for:
- C₃₄H₄₈ N₂O₆
- Calc'd:
- C, 70.32; H, 8.33; N, 4.82
- Found:
- C, 70.32; H, 8.48; N, 4.85
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 173-175°C).
- Elemental analysis for:
- C₃₄H₄₉N₃O₄
- Calc'd:
- C, 72.43; H, 8.76; N, 7.45
- Found:
- C, 72.47; H, 8.81; N, 7.48
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 147-149°C).
- Elemental analysis for:
- C₃₃H₄₆N₂O₇
- Calc'd:
- C, 68.02; H, 7.96; N, 4.81
- Found:
- C, 68.13; H, 8.03; N, 4.85
- This compound was synthesized according to the procedure outlined in Method B to yield a solid (m.p. 145-146°C).
- Elemental analysis for:
- C₃₄H₄₈N₂O₇
- Calc'd:
- C, 68.43; H, 8.11; N, 4.69
- Found:
- C, 68.24; H, 8.02; N, 4.57
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 151-153°C).
- Elemental analysis for:
- C₃₄H₄₈N₂O₆
- Calc'd:
- C, 70.32; H, 8.33; N, 4.82
- Found:
- C, 70.25; H, 8.11; N, 4.82
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 118-119°C).
- Elemental analysis for:
- C₃₅H₅₁N₃O₄
- Calc'd:
- C, 72.76; H, 8.90; N, 7.27
- Found:
- C, 72.63; H, 9.01; N, 7.33
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 120-124°C).
- Elemental analysis for:
- C₃₄H₄₉N₃O₄
- Calc'd:
- C, 72.43; H, 8.76; N, 7.45
- Found:
- C, 72.31; H, 8.54; N, 7.44
- This compound was synthesized according to the procedure outlined in Method F to yield a solid (m.p. 139-141°C).
- Elemental analysis for:
- C₃₃H₄₇N₃O₅
- Calc'd:
- C, 70.06; H, 8.37; N, 7.43
- Found:
- C, 70.11; H, 8.37; N, 7.42
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 147-148°C).
- Elemental analysis for:
- C₃₉H₄₈N₂O₄
- Calc'd:
- C, 74.42; H, 8.82; N, 5.10
- Found:
- C, 74.45; H, 8.89; N, 5.18
- This compound was synthesized according to the procedure outlined in Method B to yield a solid (m.p. 81-84°C).
- Elemental analysis for:
- C₃₆H₅₂N₂O₆
- Calc'd:
- C, 71.02; H, 8.61; N, 4.60
- Found:
- C, 71.09; H, 8.51; N, 4.59
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (m.p. 133-136°C).
- Elemental analysis for:
- C₃₅H₅₁N₃O₄
- Calc'd:
- C, 72.76; H, 8.90; N, 7.27
- Found:
- C, 72.38; H, 8.69; N, 6.98
- This compound was synthesized according to the procedure outlined in Method B to yield a solid (m.p. 196-198°C).
- Elemental analysis for:
- C₃₁H₄₁FN₂O₄
- Calc'd:
- C, 70.97; H, 7.88; N, 5.34
- Found:
- C, 70.82; H, 7.70; N, 5.32
- This compound was synthesized according to the procedure outlined in Method F to yield a solid (mp 109-112°C).
- Elemental analysis for:
- C₃₃H₄₆N₂O₅
- Calc'd:
- C, 71.97; H, 8.42; N, 5.09
- Found:
- C, 71.80; H, 8.40; N, 5.08
- This compound was synthesized according to the procedure outlined in Method B to yield a solid (mp 162-163°C).
- Elemental analysis for:
- C₃₄H₄₈FN₂O₇
- Calc'd:
- C, 68.43; H, 8.11; N, 4.69
- Found:
- C, 68.32; H, 8.14; N, 4.55
- This compound was synthesized according to the procedure outlined in Method B to yield a solid (mp 58-61°C).
- Elemental analysis for:
- C₄₄H₆₆FN₂O₆
- Calc'd:
- C, 73.50; H, 9.25; N, 3.90
- Found:
- C, 73.62; H, 9.34; N, 3.89
- This compound was synthesized according to the procedure outlined in Method K to yield a solid (mp 114-115°C).
- Elemental analysis for:
- C₃₈H₅₈N₂O₇Si
- Calc'd:
- C, 66.83; H, 8.56; N, 4.10
- Found:
- C, 66.80; H, 8.64; N, 4.01
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (mp 116-118°C).
- Elemental analysis for:
- C₃₆H₅₂N₂O₆
- Calc'd:
- C, 71.02; H, 8.61; N, 4.60
- Found:
- C, 70.68; H, 8.66; N, 4.63
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (mp 116-118°C).
- Elemental analysis for:
- C₃₆H₅₃N₃O₄
- Calc'd:
- C, 73.06; H, 9.03; N, 7.10
- Found:
- C, 73.18; H, 9.31; N, 7.40
- This compound was synthesized according to the procedure outlined in Method G to yield a solid (mp 116-118°C).
- Elemental analysis for:
- C₃₂H₄₄N₂O₇
- Calc'd:
- C, 67.58; H, 7.80; N, 4.93
- Found:
- C, 67.43; H, 8.02; N, 4.80
- This compound was synthesized according to the procedure outlined in Method M t yield a solid (mp 204-206°C).
- Elemental analysis for:
- C₄₀H₆₀N₂O₅
- Calc'd:
- C, 74.04; H, 9.32; N, 4.32
- Found:
- C, 73.96; H, 9.45; N, 4.57
- To a solution of 6.4 g (25.6 mmol) of 5-[bis(methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione and 4.84 (56.0 mmol) of sodium bicarbonate in 10 mL of degassed DMSO was added 10.0 g (36.0 mmol) of 3,5-di-t-butyl-4-hydroxyaniline hydrochloride in 30 mL degassed DMSO over a 5 h period at room temperature. Stirring was continued for an additional 19 h. The reaction mixture was poured into cold H₂O and the product filtered. The solid was dried and dissolved in ethyl acetate and flitered again. The solvent was removed at reduced pressure and the residue submitted to a column chromatography on silica gel (3:1 to 2:1 Hexane-ethyl acetate) to yield 9.8 g (90%) of a solid that was used without further purification.
- To a solution of 0.84 g (2.0 mmol)of the compound from above in 20 mL of 1:1 t-butanol-acetonitrile was added 0.55 g (2.0 mmol) of N-4-neopentybenzyl-N- heptylamine, 0.36 g (1.2 mmol) of mercuric sulfate and 0.28 mL (2.0 mmol) of triethylamine. The reaction mixture was allowed to reflux for 4 hours. The solution was cooled to room temperature, diluted with ethyl acetate and filtered through celite. The solvent was removed under reduced pressure and column chromatography of the residue on silica gel (1:2 to 2:1 ethyl acetate-hexanes) yielded 0.98 g (75%) of a pale yellow solid (m.p. 96-100°C)homogenous by spectroscopic considerations. IR (KBr): 3220, 2950, 2860, 1696, 1624, 1465, 1429, 1382, 1358, 1262, 1229, 1198, 1112, 1086, 921 and 779 cm⁻¹; ¹H NMR (400 MHz, CDCl₃: d 7.18 (d, 2H, J = 7.88 Hz), 7.09 (d, 2H, J = 8.08 Hz), 6.89 (s, 2H), 5.22 (s, 1H), 4.39 (s, 2H), 3.14 (m, 2H), 2.46 (s, 2H), 1.70-1.55 (m, 8H), 1.38 (s, 18H), 1.24-1.14 (m, 8H) (s, 9H) (t, 3H, J = 6. 84 Hz).
- Elemental analysis for:
- C₄₀H₆₀N₂O₅
- Calc'd:
- C, 74.04; H, 9.32; N, 4.32
- Found:
- C, 73.93; H, 9.39; N, 4.26
- This compound was synthesized according to the procedure outlined in Example 76 above to yield a solid (mp 120-122°C).
- Elemental analysis for:
- C₃₈H₅₆N₂O₅
- Calc'd:
- C, 73.51; H, 9.09; N, 4.51
- Found:
- C, 73.37; H, 8.80; N, 4.57
- This compound was synthesized according to the procedure outlined in Method F to yield a solid (mp 58-60°C).
- Elemental analysis for:
- C₃₉H₅₀N₂O₆
- Calc'd:
- C, 72.87; H, 7.84; N, 4.36
- Found
- C, 72.24; H, 7.82; N, 4.33
- This compound was synthesized according to the procedure outlined in Example 76 to yield a solid (mp 162-164°C).
- Elemental analysis for:
- C₃₉H₅₈N₂O₅
- Calc'd:
- C, 73.78; H, 9.21; N, 4.41
- Found:
- C, 73.47; H, 8.98; N, 4.16
- To a solution of 7.06 g (71.2 mmol) of cyclohexylamine and 14.41 g ( 142.4 mmol) of triethylamine in 150 mL of CHCl₃ at 0°C was added 140 g (71.2 mmol) of 4-neopentylbenzoyl chloride dropwise. The reaction mixture stirred at 0°C for 1 hour then to room temperature for 67 hours. This mixture was added to 150 mL of H₂O and the organic layer was separated then washed with 150 mL of H₂O. The chloroform layer was dried (Na₂SO₄) and the solvents were removed at reduced pressure. The solid obtained was used without further purification or characterization.
- To a solution of 19.9 g (71.2 mmol) of the amide from the preceding paragraph, 250 mL of toluene at 0°C was added 41.9 mL of 3.4 M Red-Al dropwise. After addition the solution stirred at 0°C for 10 minutes and was warmed to reflux for 18 hours. The reaction mixture was quenched with aqueous NH₄Cl and the solvent removed at reduced pressure. The residue was taken up in 350 mL of H₂O and acidified to pH = 2 with concentrated HCl. The aqueous layer was extracted with CHCl₃ (3 x 150 mL) which were combined, dried (MgSO₄) and the solvent removed at reduced pressure. The amine-hydrochloride salt was triturated with hexane then filtered. The salt was added to 600 mL of H₂O and the pH raised to 14 with solid NaOH. This was extracted with diethyl ether (4 x 125 mL). The combined ether layers were dried (Na₂SO₄) and the solvent removed at reduced pressure. The amine was used without further purification or characterization.
- To a solution of 0.8 g (1.0 mmol) of the compound from Method M, procedure 1 in 20 mL of acetonitrile was added 0.49 g (1.9 mmol) of N-4-neopentylbenzyl-N-cyclohexylamine, 0.34 g (1.14 mmol) of mercuric sulfate and 0.26 mL (1.9 mmol) triethylamine. This solution was stirred at reflux for 2.5 hours. The solution was cooled to room temperature and filtered through celite which was washed with ethyl acetate. The solvents were removed at reduced pressure and column chromatography of the residue on silica gel (40% hexanes-3% triethylamine - 57% ethyl acetate), yielded 1.0 g (83%) which was recrystallized from diethyl ether (mp 165-167°C). IR (KBr) 3430, 2945, 2858, 1625, 1568, 1482, 1431, 1382, 1253, 1229, 1196, 1157, 1091, 1006, 926, 886, 780 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 7.26-7.13 (m, 4H), 6.87 (s, 2H), 5.22 (s, 1H), 4.64 (br s, 2H), 4.14 (br s, 1H), 2.47 (s, 2H), 2.08 (m, 2H), 1.76 (m, 2H), 1.57 (s, 6H), 1.42-1.25 (m, 27H), 0.88 (s, 9H).
- Elemental Analysis for:
- C₃₉H₅₆N₂O₅
- Calc'd:
- C, 74.01; H, 8.92; N, 4.43
- Found:
- C, 74.19; H, 8.66; N, 4.42
- The ability of the compounds of this invention to inhibit acyl-coenzyme A: cholesterol acyltransferase was established by initially showing that they inhibited intracellular cholesterol esterification by subjecting them to the standard experimental test procedure of Ross et al., J. Biol. Chem. 259 815 (1984).
- Representative compounds were further tested in vivo to establish the percent inhibition of cholesterol absorption. In this study, normal rats were dosed (oral gavage) with ¹⁴C-cholesterol plus the test compound. Blood samples taken at six hours and/or intermittently up to twenty-four hours were analyzed and the percent inhibition of cholesterol absorption was calculated.
- In addition, representative compounds were studied in vivo in cholesterol-cholic acid fed rats to determine the percent decrease of cholesterol in their plasma. This study involves rats which are, prior to testing, trained for one week to eat over a four hour time period each day. Upon initiation of the experiment, the rats diet is supplemented with 1.0 percent cholesterol and 0.25 percent cholic acid. The rats are dosed with the test compound by oral gavage just prior to adjust following the four hour feeding period. This is repeated for four days. On the fifth day, the rats are sacrificed and the total plasma cholesterol content is determined. The percent decrease in elevated plasma cholesterol levels is calculated in comparison with normal-fed controls.
-
-
- From these data, the ability of the compounds to inhibit ACAT is clearly established. Hence, the compounds of this invention are useful in the treatment of those disease states which are amenable to treatment by reduction of the rate of cholesterol esterification, the rate of accumulation and deposits of cholesteryl esters on arterial walls and the rate of formation of atheromatous lesions. As such, the anti-atherosclerotic agents of this invention may be administered to a mammal in need of intracellular cholesteryl ester concentration reduction orally or parenterally in an amount sufficient to inhibit ACAT catalysis of cholesterol esterification.
- In addition to ACAT inhibition, some of the compounds of this invention possess excellent antioxidant properties when examined in the manner disclosed by Parthasarathy et al., J. Clin. Invest., 77, 641 (1986) in low density lipoprotein oxidation studies and in the lipoperoxide study of Yagi, Biochemical Medicine, 15, 212 (1976). The products of Examples 75, 76, 77 and 79, supra, are demonstrated antioxidant properties in these standard procedures, representative of the other antioxidants of this invention. The use of antioxidants in the treatment of atherosclerosis is also known to be of therapeutic value.
- The compounds of this invention may be administered by themselves or in combination with pharmaceutically acceptable liquid or solid carriers. Oral administration in conventional formulations as tablets, capsules, powders, or suspensions is preferred.
- A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilisers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable propoitions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
- Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both of pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilisers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oil ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellent.
- Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. When the compound is orally active, it can be administered orally either in liquid or solid composition form.
- Preferably, the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
- The dosage to be used in the treatment of a specific hypercholesterolemic/atherosclerotic condition must be subjectively determined by the attending physician. The variables involved include the extent of the disease state, size, age and response pattern of the patient.
to give a compound of formula I as defined above wherein R₁ is hydrogen;
and if desired after said process a) or b) converting any value of X, Y or Z to one of the other values for X, Y and Z by known methods and further if desired isolating the product as a pharmaceutically acceptable salt.
Claims (21)
- A compound of the formula:
X, Y and Z are, independently, hydrogen, halogen, hydroxy, nitro, cyano, carboxyl, trifluoromethyl, phenyl, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group has 1 to 6 carbon atoms, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms or phenylalkyloxy of 7 to 9 carbon atoms;
R₁ is alkyl of 1 to 18 carbon atoms, hydroxyalkyl of 1 to 18 carbon atoms, alkenyl of 1 to 18 carbon atoms, cycloalkyl of 5 to 8 carbon atoms, phenylcycloalkyl in which the cycloalkyl moiety has 5 to 8 carbon atoms, 1-hydroxymethylphenethyl, 1-(t-butyl)dimethylsilyloxymethylphenethyl, 1-(t-butyl)dimethylsilyloxymethylisopentyl, 1-hydroxymethylisopentyl, phenyl, benzyl or substituted phenyl or benzyl where the substituents are alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, halogen, cyano, trifluoromethyl, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group has 1 to 6 carbon atoms, nitro, phenyl, benzyl or phenethyl or R¹ is thienyl, imidazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, benzamidazolyl, phenylalkylpiperidinyl in which the alkyl moiety has from 1 to 6 carbon atoms or morpholino or R¹ is hydrogen;
R₂ is alkyl of 1 to 18 carbon atoms, cycloalkyl of 5 to 8 carbon atoms, phenyl, benzyl or substituted phenyl or benzyl in which said substituent is alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, halogen, cyano, trifluoromethyl, amino, nitro, alkylamino of 1 to 6 carbon atoms or dialkylamino of 1 to 6 carbon atoms;
or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical. - A compound of formula I or a pharmaceutically acceptable salt thereof as defined in Claim 1 where R₁ is other than hydrogen.
- A compound as claimed in Claim 1 or Claim 2 in which X, Y and Z are independently , alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, hydroxy, dialkylamino in which each alkyl group has from 1 to 6 carbon atoms or aralkoxy of 7 to 10 carbon atoms;
- A compound as claimed in any one of Claims 1 to 3 in which R₁ is alkyl of 1 to 18 carbon atoms, 1-(t-butyl)dimethylsilyloxymethylphenethyl, 1-(t-butyl)dimethylsilyloxymethylisopentyl, phenylcycloalkyl in which the cycloalkyl group has 5 to 8 carbon atoms or hydroxy alkyl of 1 to 18 carbon atoms.
- A compound as claimed in anyone of Claims 1 to 4 in which R₂ is alkyl- or alkoxy-substituted benzyl, in which the alkyl and alkoxy substituents contain 1 to 6 carbon atoms.
- A compound as claimed in Claim 2 which is 5-[[(2,4-dimethoxyphenyl)amino][(1-methylhexyl)[[4-(2-methylpropyl)phenyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is 5-[[[2,6-dimethyl-4-(dimethylamino)phenyl]amino][[[4-(2,2-dimethylpropyl)phenyl]methyl](1-methylhexyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is 5-[[[4-(dimethylamino)phenyl]amino][[[4-(2,2-dimethylpropyl)phenyl]methyl](1-methylhexyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is 5-[[(2,4-dimethoxyphenyl)amino][(1-methylhexyl)[(4-pentylphenyl)methyl]amino]methylene]-2,2-methyl-1,3-dioxane-4,6-dione or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is 5-[[[4-(dimethylamino)phenyl]amino][(1-methylhexyl)[(4-pentylphenyl)methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is 5-[[[4-(dimethylamino)-2-methylphenyl]amino][(1-methylhexyl)[[4-(2-methylpropyl)phenyl]methyl]amino]methylene]-2,3-dimethyl-1,3-dioxane-4,6-dione or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is 5-[[[4-(dimethylamino)-2-methylphenyl]amino][[[4-(2,2-dimethylpropyl)phenyl]methyl](1-methylhexyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is 5-[[[4-(dimethylamino)-2-methylphenyl]amino][(1-methylhexyl)[(4-pentylphenyl)methyl]amino]methylene]-2-dimethyl or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is 5-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]amino][(1-methylhexyl)[[4-(2,2-dimethylpropyl]phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is 5-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]amino][[[4-(2,2-dimethylpropyl)phenyl]methyl]heptylamino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is 5-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]amino][hexyl[[4-(2-methylpropyl)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is 5-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]amino][[[4-(2,2-dimethylpropyl)phenyl]methyl]hexylamino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is 5-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]amino][cyclohexyl[[4-(2,2-dimethylpropyl)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione or a pharmaceutically acceptable salt thereof.
- A compound as claimed in Claim 2 which is one of the following:
3-[(dihexylamino)[(2,4-dimethoxyphenyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][[[4-(1,1-dimethylethyl) phenyl]methyl]heptylamino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[(dihexylamino)[(4-fluorophenyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(dimethylamino)phenyl]amino][[[4-(1,1-dimethylethyl)phenyl]methyl]heptylamino]-methylene]2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(-2,4-dimethoxyphenyl)amino][heptyl[[4-[(3-methylbutyl)oxy]phenyl]methyl]amino]-methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][[[4-(2-methylpropyl)phenyl]methyl][1-(phenylmethyl)-4-piperidinyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][[(1-phenylcyclopentyl) methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][[[4-(2,2-dimethylpropyl)phenyl]methyl][(1-phenylcyclo-pentyl)methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][(R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-phenylethyl][[4-(2-methylpropyl)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
(R)-5-[[(2,4-dimethoxyphenyl)amino][[(1R)-1-(hydroxymethyl)-2phenylethyl][[4-(2-methyl- propyl)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]amino][(1-methyl(hexyl)[[4(2-methylpropyl)phenyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][heptyl[(4-pentylphenyl)methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-difluorophenyl)amino][[[4-(1,1-dimethylethyl)phenyl]methyl]heptylamino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(dimethylamino)-2,6-dimethylphenyl]amino][[[4-(1,1-dimethylethyl)phenyl]methyl]heptylamino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(trifluoromethyl)phenyl]amino][heptyl[(4-pentylphenyl)methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-difluorophenyl)amino][[(4-hexylphenyl)methyl]heptylamino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(4-butoxyphenyl)amino][[[4-(1,1-dimethylethyl)phenyl]methyl]heptylamino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[[4-(1,1-dimethylethyl)phenyl]methyl](1-methylhexyl)amino][3,4,5-trimethoxyphenyl)-amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(dimethylamino)phenyl]amino][[[4-(1,1-dimethylethyl)phenyl]methyl](1-methylhexyl)-amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(dimethylamino)phenyl] amino][heptyl[[[4-(3-methylbutyl)oxy]phenyl]methyl]amino]-methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[heptyl[[4-[(3-methylbutyl)oxy]phenyl]methyl]amino][(3,4,5-trimethoxyphenyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[[4-(1,1-dimethylethyl)phenyl]methyl]heptylamino][[4-(pentyloxy)phenyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[[4-(1,1-dimethylethyl)phenyl]methyl]heptylamino][[4-(hexyloxy)phenyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[[4-(1,1-dimethylethyl)phenyl]methyl]heptylamino][[4-(phenylmethoxy)phenyl]amino]-methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(4-butoxyphenyl)amino][[[4-(1,1-dimethylethyl)phenyl]methyl](1-methylhexyl)amino]-methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(4-butoxyphenyl)amino][[[4-(1,1-dimethylethyl)phenyl]methyl](1,5-dimethylhexyl)amino]-methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][[[4-(1,1-dimethylethyl)phenyl]methyl](1,5-dimethylhexyl)-amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[[4-(1,1-dimethylethyl)phenyl]methyl]heptylamino][[4-(trifluoromethyl)phenyl]amino]-methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][heptyl[[4-(2-methylpropyl)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
2,2-dimethyl-5-[[(1-methylhexyl)[[4-(2-methylpropyl)phenyl]methyl]amino][[(3-phenylmethoxy)phenyl]amino]methylene]-4,6-dione;
5-[[2,4-dimethoxyphenyl][[[4-(3-methylbutoxy)phenyl]methyl](1-methylhexyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(dimethylamino)phenyl]amino][(1-hexylheptyl)[[4-(2-methylpropyl)phenyl]methyl]-amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[-4-(dimethylamino)phenyl]amino][[[4-(3-methylbutoxy)phenyl]methyl](1-methylhexyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][(1,5-dimethylhexyl)[[4-(2-methylpropyl)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(dimethylamino)phenyl]amino][[[4-(2-methylpropyl)phenyl]methyl](1,5-dimethylhexyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(hexyloxy)phenyl]amino][(1-methylhexyl)[[4-(2-methylpropyl)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[(4-butylphenyl)methyl](5-hydroxy-1,5-dimethylhexyl)amino][(2,4-dimethoxyphenyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[(4-butylphenyl)methyl](5-hydroxy-1,5-dimethylhexyl)amino][[4-(dimethylamino)phenyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-((dimethylamino)phenyl]amino][[[4-(2-methylpropyl)phenyl]methyl][1-(phenylmethyl)-4-piperidinyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][[1-methyl-2(4-morpholinyl)ethyl][[4-(2-methylpropyl)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-dimethylamino)phenyl]amino][[1-methyl-2-(4-morpholinyl)ethyl][[4-(2-methylpropyl)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[2,4-dimethoxyphenyl)amino][(5-hydroxy-1,5-dimethylhexyl)[[4-(2methylpropyl)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(dimethylamino)phenyl]amino][(5-hydroxy-1,5-dimethylhexyl)[[4-(2-methylpropyl)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][heptyl[[4-(3-methylbultyl)phenyl]methyl]-amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][[[4-(3-methylbutyl)phenyl]methyl](1-methylhexyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-dimethylamino)phenyl]amino][[[4-(3-methylbultyl)phenyl]methyl](1-methylhexyl)-amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[2,4-dimethoxyphenyl)amino][(1-methylhexyl)[[4-(2-methylpropoxy)-phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[[4-(1,1-dimethylethyl)phenyl]methyl]heptylamino][(2,4,6-trimethoxyphenyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][[[4-(2,2-dimethylpropyl)phenyl]methyl](1-ethylpentyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(dimethylamino)-2-methylphenyl]amino][[[4-(3-methylbutyl)phenyl]methyl](1-methylhexyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(dimethylamino)phenyl]amino][[[4-(2,2-dimethylpropyl)phenyl]methyl](1-ethylpentyl)-amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-dimethylamino)phenyl]amino][(1-methylhexyl)[[4-(2-methylpropoxy)phenyl]methyl] amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6 dione;
5-[[(2,4-dimethylphenyl)amino][[[4-(2,2-dimethylpropyl)phenyl]methyl](1-methylhexyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[decyl[[4-(1,1-dimethylethyl)phenyl]methyl]amino][(2,4-dimethoxyphenyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(dimethylamino)-2-methylphenyl]amino][[[4-(2,2-dimethylpropyl)phenyl]methyl](1-ethylpentyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[[4-(1,1-dimethylethyl)phenyl]methyl]hexylamino][(4-fluorophenyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[2,4-dimethylphenyl)amino][(1-methylhexyl)[[4-(2-methylpropoxy)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[[4-(1,1-dimethylethyl)phenyl]methyl]heptylamino][3,4,5-trimethoxyphenyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][[[4-(1,1-dimethylethyl)phenyl]methyl]((Z)-9-octadecenyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-2,4-dione;
5-[[(2,4-dimethoxyphenyl]amino][[(R)-1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3-methylbutyl][[4-(2-methylpropyl)phenyl]methyl]amino]methylene-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[(2,4-dimethoxyphenyl)amino][[[4-(3-methylbutyl)phenyl]methyl][3-methyl-1-(2-methylpropyl)butyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[[4-(dimethylamino)phenyl]anino][[[4-(3-methylbutyl)phenyl]methyl][3-methyl-1-(2-methylpropyl)butyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
(R)-5-[[(2,4-dimethoxyphenyl)anino][[1-(hydroxymethyl)-3-methylbutyl][[4-(2-methylpropyl)phenyl]methyl]amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
5-[[heptyl[[4-(3-methylbutoxy)phenyl]methyl]amino][[3-(phenylmethoxy)phenyl] amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione;
or a pharmaceutically acceptable salt thereof. - A process for preparing a compound of formula I as defined in Claim 1 or a pharmaceutically acceptable salt thereof which comprisesa) reacting a compound of formula
orb) reacting 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's Acid) with a carbodiimide of formula
and if desired after said process a) or b) converting any value of X, Y or Z to one of the other values for X, Y and Z by known methods and further if desired isolating the product as a pharmaceutically acceptable salt. - A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof as defined in any one of Claim 1 to 19 and a pharmaceutically acceptable carrier.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56838490A | 1990-08-16 | 1990-08-16 | |
US568384 | 1990-08-16 | ||
US719873 | 1991-06-24 | ||
US07/719,873 US5179216A (en) | 1990-08-16 | 1991-06-24 | N,n', n'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-coa:cholesterol-acyl transferase |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0471493A1 true EP0471493A1 (en) | 1992-02-19 |
EP0471493B1 EP0471493B1 (en) | 1996-05-22 |
Family
ID=27074770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91307196A Expired - Lifetime EP0471493B1 (en) | 1990-08-16 | 1991-08-06 | N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA:cholesterol-acyl transferase |
Country Status (20)
Country | Link |
---|---|
US (1) | US5179216A (en) |
EP (1) | EP0471493B1 (en) |
JP (1) | JPH04244078A (en) |
KR (1) | KR920004373A (en) |
AT (1) | ATE138373T1 (en) |
AU (1) | AU639129B2 (en) |
CA (1) | CA2048891A1 (en) |
CZ (1) | CZ280881B6 (en) |
DE (1) | DE69119665T2 (en) |
DK (1) | DK0471493T3 (en) |
ES (1) | ES2088469T3 (en) |
FI (1) | FI913894A (en) |
GB (1) | GB2247019B (en) |
GR (1) | GR3020776T3 (en) |
HU (2) | HUT58717A (en) |
IE (1) | IE65711B1 (en) |
IL (1) | IL99065A (en) |
MX (1) | MX9203265A (en) |
NZ (1) | NZ239413A (en) |
PT (1) | PT98675A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0531119A1 (en) * | 1991-09-06 | 1993-03-10 | American Home Products Corporation | N,N',N'-trisubstituted -5-bis-aminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase |
FR2781222A1 (en) * | 1998-07-17 | 2000-01-21 | Lipha | New cyclic peroxisome proliferator activated receptor activators, used to prevent or treat dyslipidemia, atherosclerosis and diabetes |
EP1143965A1 (en) * | 1998-10-30 | 2001-10-17 | Merck & Co., Inc. | Carbocyclic potassium channel inhibitors |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5391768A (en) * | 1993-03-25 | 1995-02-21 | United States Surgical Corporation | Purification of 1,4-dioxan-2-one by crystallization |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1147759A (en) * | 1965-06-17 | 1969-04-10 | Sterling Drug Inc | Aromatic derivatives and preparation thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4387105A (en) * | 1982-01-26 | 1983-06-07 | American Cyanamid Company | Methods of treating atherosclerosis with dialkylureas and dialkylthioureas |
US4387106A (en) * | 1982-01-26 | 1983-06-07 | American Cyanamid Company | Method of treating atherosclerosis with di(aralkyl)ureas and di(aralkyl)thioureas |
-
1991
- 1991-06-24 US US07/719,873 patent/US5179216A/en not_active Expired - Lifetime
- 1991-08-02 IL IL9906591A patent/IL99065A/en not_active IP Right Cessation
- 1991-08-06 DE DE69119665T patent/DE69119665T2/en not_active Expired - Fee Related
- 1991-08-06 JP JP3196550A patent/JPH04244078A/en active Pending
- 1991-08-06 DK DK91307196.5T patent/DK0471493T3/en active
- 1991-08-06 AT AT91307196T patent/ATE138373T1/en not_active IP Right Cessation
- 1991-08-06 EP EP91307196A patent/EP0471493B1/en not_active Expired - Lifetime
- 1991-08-06 GB GB9116965A patent/GB2247019B/en not_active Expired - Fee Related
- 1991-08-06 ES ES91307196T patent/ES2088469T3/en not_active Expired - Lifetime
- 1991-08-09 CA CA002048891A patent/CA2048891A1/en not_active Abandoned
- 1991-08-14 AU AU82430/91A patent/AU639129B2/en not_active Ceased
- 1991-08-14 PT PT98675A patent/PT98675A/en not_active Application Discontinuation
- 1991-08-14 KR KR1019910014000A patent/KR920004373A/en active IP Right Grant
- 1991-08-15 HU HU912716A patent/HUT58717A/en unknown
- 1991-08-15 NZ NZ239413A patent/NZ239413A/en unknown
- 1991-08-15 IE IE290091A patent/IE65711B1/en not_active IP Right Cessation
- 1991-08-16 FI FI913894A patent/FI913894A/en not_active Application Discontinuation
- 1991-08-16 CZ CS912552A patent/CZ280881B6/en unknown
-
1992
- 1992-06-24 MX MX9203265A patent/MX9203265A/en unknown
-
1995
- 1995-06-20 HU HU95P/P00290P patent/HU211555A9/en unknown
-
1996
- 1996-08-12 GR GR960402145T patent/GR3020776T3/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1147759A (en) * | 1965-06-17 | 1969-04-10 | Sterling Drug Inc | Aromatic derivatives and preparation thereof |
Non-Patent Citations (5)
Title |
---|
CHEMICAL ABSTRACTS, vol. 71, no. 23, 8 December 1969, Columbus, Ohio, US; abstract no. 112900, H. BOEHME et al: 'Cleavage of aminals and 1,3-dialkylamidazolidines with heterocumulenes' pages 378-379& ARCH. PHARM. (WEINHEIM), 1969, 51(5), 479-483 * |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 10, October 1989, WASHINGTON, DC, US, pages 2318 - 2325; V.G. DE VRIES ET AL: 'Potential antiatherosclerotic agents. 6. Hypocholesterolemic trisubstituted urea analogues' * |
SYNTHESIS, no. 4, April 1989, Stuttgart, DE, pages 317 - 320; F.-C. YE ET AL: 'Synthesis of 7-substituted 5-oxo-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic acids, 2-substituted 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acids, and 2,6-disubstituted 4-quinolones from Meldum's acid derivatives' EP 91307196030 * |
WISSENSCHAFTLICHE ZEITSCHRIFT - MARTIN-LUTHER-UNIVERSITÄT HALLE-WITTENBERG, MATHEMATISCH-NATURWISSENSCHAFTLICHE REIHE vol. 38, no. 3, 1989, Halle, DD, pages 27 - 36; M. AUGUSTIN ET AL: 'Ringschlussrektion mit Keten-S,N bzw. -aminalen des 2,2-Dimethyl-1,3-dioxan-4,6-dions (Meldrumsäure)' EP 91307196030 * |
ZEITSCHRIFT FÜR CHEMIE, vol. 30, no. 5, May 1990, Leipzig, DE, pages 169 - 170; M. AUGUSTIN ET AL: 'Synthese von 5-(Diaminomethylen)-2,2-dimethyl-1,3-dioxan-2,4-dionen' * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0531119A1 (en) * | 1991-09-06 | 1993-03-10 | American Home Products Corporation | N,N',N'-trisubstituted -5-bis-aminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase |
FR2781222A1 (en) * | 1998-07-17 | 2000-01-21 | Lipha | New cyclic peroxisome proliferator activated receptor activators, used to prevent or treat dyslipidemia, atherosclerosis and diabetes |
WO2000004011A1 (en) * | 1998-07-17 | 2000-01-27 | Merck Patent Gmbh | Cyclic compounds useful in the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions and preparation process |
US6528538B1 (en) | 1998-07-17 | 2003-03-04 | Merck Patentgesellschaft | Cyclic compounds useful in the treatment of dyslipidaemia, atherosclerosis and diabetes, pharamaceutical compositions and preparation process |
EP1143965A1 (en) * | 1998-10-30 | 2001-10-17 | Merck & Co., Inc. | Carbocyclic potassium channel inhibitors |
EP1143965A4 (en) * | 1998-10-30 | 2002-10-09 | Merck & Co Inc | Carbocyclic potassium channel inhibitors |
US6632836B1 (en) | 1998-10-30 | 2003-10-14 | Merck & Co., Inc. | Carbocyclic potassium channel inhibitors |
Also Published As
Publication number | Publication date |
---|---|
IL99065A0 (en) | 1992-07-15 |
FI913894A0 (en) | 1991-08-16 |
HUT58717A (en) | 1992-03-30 |
AU639129B2 (en) | 1993-07-15 |
US5179216A (en) | 1993-01-12 |
NZ239413A (en) | 1993-03-26 |
IE65711B1 (en) | 1995-11-15 |
DE69119665D1 (en) | 1996-06-27 |
AU8243091A (en) | 1992-02-20 |
KR920004373A (en) | 1992-03-27 |
DK0471493T3 (en) | 1996-06-24 |
CA2048891A1 (en) | 1992-02-17 |
IL99065A (en) | 1996-01-31 |
PT98675A (en) | 1992-07-31 |
GB2247019A (en) | 1992-02-19 |
FI913894A (en) | 1992-02-17 |
GB9116965D0 (en) | 1991-09-18 |
MX9203265A (en) | 1992-07-01 |
ATE138373T1 (en) | 1996-06-15 |
CS255291A3 (en) | 1992-03-18 |
IE912900A1 (en) | 1992-02-26 |
DE69119665T2 (en) | 1997-01-02 |
JPH04244078A (en) | 1992-09-01 |
ES2088469T3 (en) | 1996-08-16 |
HU211555A9 (en) | 1995-12-28 |
EP0471493B1 (en) | 1996-05-22 |
HU912716D0 (en) | 1992-01-28 |
GR3020776T3 (en) | 1996-11-30 |
GB2247019B (en) | 1994-04-13 |
CZ280881B6 (en) | 1996-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0373423B1 (en) | Substituted 2-pyridones and pyride-2-thiones, process for their preparation and their use in medicine | |
US4668794A (en) | Intermediate imidazole acrolein analogs | |
US5776951A (en) | Anti-atherosclerotic diaryl compounds | |
US5510379A (en) | Sulfonate ACAT inhibitors | |
JP3100984B2 (en) | Catechol diethers as selective PDE lower I lower V lower inhibitors | |
CA2368148A1 (en) | Novel compounds and compositions as protease inhibitors | |
US4699992A (en) | 3-amino-2-benzoylacrylic acid derivatives | |
EP0767170A1 (en) | Novel 4,6-diarylpyrimidine derivatives and salts thereof | |
US4847379A (en) | 3,6-dihydro-1,5(2H)-pyrimidinecarboxylic acid esters | |
US4460607A (en) | Lipid absorption-inhibiting agents and their use | |
EP0471493B1 (en) | N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA:cholesterol-acyl transferase | |
EP0367895A1 (en) | Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them | |
EP0556308B1 (en) | Oxysulfonyl urea acat inhibitors | |
US5380853A (en) | N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-coa:cholesterol-acyl transferase | |
IE48320B1 (en) | Heterocyclylcarbonyl derivatives of urea and their use as agents for dissolution of gallstones | |
JP3541384B2 (en) | Oxysulfonyl carbamate | |
NO173057B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE BENZANILIDE DERIVATIVES | |
HU220971B1 (en) | Process for producing 0-(3-amino-2-hidroxy-propyl)-hidroxim acid halogenids | |
JP4083800B2 (en) | Anti-ischemic hydroxylamine derivatives and pharmaceutical compositions | |
EP0531119B1 (en) | N,N',N'-trisubstituted -5-bis-aminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase | |
Azizian et al. | A rapid and highly efficient one-pot methodology for preparation of alkyl oxindolideneacetates | |
JPH01261375A (en) | Substituted imidazolines and imidazolithiones | |
US5136039A (en) | N,N',N'-trisubstituted-5-bis-aminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA:cholesterol-acyl transferase | |
US5164505A (en) | N-phenyl-N'-alkyl-N'-pyridylmethyl-bis-diamino-5-methylene-1,3-dioxane-4,6-diones | |
US5177219A (en) | N-phenyl-N'-thienylmethyl-bis-diamino-5-methylene-1,3-dioxane-4,6-dione compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GR IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19920711 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AMERICAN HOME PRODUCTS CORPORATION |
|
17Q | First examination report despatched |
Effective date: 19941006 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GR IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 138373 Country of ref document: AT Date of ref document: 19960615 Kind code of ref document: T |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19960618 Year of fee payment: 6 |
|
ITF | It: translation for a ep patent filed |
Owner name: BARZANO' E ZANARDO MILANO S.P.A. |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19960627 Year of fee payment: 6 |
|
REF | Corresponds to: |
Ref document number: 69119665 Country of ref document: DE Date of ref document: 19960627 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19960701 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 19960703 Year of fee payment: 6 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: BA2A Ref document number: 2088469 Country of ref document: ES Kind code of ref document: T3 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19960716 Year of fee payment: 6 |
|
ET | Fr: translation filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 19960802 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19960813 Year of fee payment: 6 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2088469 Country of ref document: ES Kind code of ref document: T3 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19960830 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19960831 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19960911 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 19960923 Year of fee payment: 6 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3020776 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970806 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970806 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970806 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970807 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970807 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970831 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970831 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970831 |
|
BERE | Be: lapsed |
Owner name: AMERICAN HOME PRODUCTS CORP. Effective date: 19970831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980301 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980501 |
|
EUG | Se: european patent has lapsed |
Ref document number: 91307196.5 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19980301 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 19980910 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050806 |